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Resumo 
 
 
 As actuais abordagens terapêuticas para cancro de próstata (PCa) 
avançado são limitadas e ineficazes. Uma vez que as aberrações epigenéticas 
são muito comuns em PCa, o uso terapêutico de fármacos epigenéticos pode 
ser uma alternativa viável. A variante de histona H2A.Z e sua forma acetilada 
têm sido associadas com a activação de oncogenes em células de PCa, 
devido à sua localização perto do TSS. Assim, objetivou-se avaliar o efeito de 
fármacos epigenéticos na regulação da expressão da variante H2A.Z. 
 Três linhas celulares de PCa (LNCaP, DU145 e PC-3) foram tratadas 
com 5-aza-2'-desoxicitidina (DAC) e tricostatina A (TSA). Os níveis de 
transcripto e proteína dos genes H2AFZ e SIRT1 foram avaliados por qRT-
PCR e Western Blot, respectivamente. ChIP foi realizado para avaliar em que 
medida o tratamento alterava o padrão de marcas de histonas. 
Subsequentemente, a exposição a nicotinamida e resveratrol, um inibidor e um 
indutor de actividade sirtuina 1, respectivamente, foi realizada para avaliar o 
papel da sirtuina 1 nos níveis H2A.Z. Além disso, um ensaio de ligação 
proximal (PLA) foi realizado para avaliar a capacidade dos farmacos 
epigenéticos em regular a interacção entre a sirtuina 1 e a H2A.Z. 
 O tratamento com TSA, sozinho ou combinado com DAC, levou a um 
aumento dos níveis de transcripto do gene H2AFZ, embora com uma 
simultânea diminuição dos níveis de proteína. Por outro lado, os níveis de 
transcripto e de proteína do gene SIRT1 aumentaram após a exposição aos 
fármacos. O ChIP revelou um aumento de marcas de activação da transcrição 
na região do TSS para ambos os genes. Surpreendentemente, após a inibição 
da sirtuina 1, níveis H2A.Z aumentaram abruptamente, enquanto que a 
indução da sirtuina 1 levou a uma queda abrupta nos níveis de H2A.Z. 
Finalmente, os resultados de PLA mostraram que os fármacos epigenéticos 
favorecem a interacção entre as duas proteínas estudadas. 
 Embora os fármacos epigenéticos sejam capazes de regular a 
transcrição de ambos os genes, a falta de correlação entre os níveis de mRNA 
e proteína para H2A.Z sugerem o envolvimento de um mecanismo pós-
translacional. De facto, a sirtuina 1 tem a capacidade de degradar H2A.Z, tal 
como previamente descrito para cardiomiócitos. Desta forma, os níveis de 
proteína H2A.Z são indirectamente regulados por fármacos epigenéticos, 
provavelmente através da sobreregulação do gene SIRT1. Em tumores 
primários da próstata, a sobreexpressão de H2AFZ e subexpressão de I 
validam os dois genes como alvos de tratamento epigenético. 
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abstract 
 
           Current therapeutic approaches for advanced prostate cancer (PCa) are 
limited and mostly ineffective. Because epigenetic aberrations are common in 
PCa, the therapeutic use of epigenetic modulating drugs might provide a 
therapeutic alternative. The histone variant H2A.Z and its acetylated form have 
been previously associated with activation of oncogenes owing to their location 
near the TSS in PCa cells. Thus, we aimed to evaluate the effect of epigenetic 
modulating drugs on H2A.Z expression. 
 Three PCa cell lines (LNCaP, DU145 and PC-3) were treated with 5-
aza-2’-deoxycytidine (DAC) and trichostatin A (TSA). Transcript and protein 
levels of H2AFZ and SIRT1 were assessed by quantitative RT-PCR and 
Western blot, respectively. ChIP was performed to evaluate how treatment 
altered the pattern of histone marks. Subsequently, exposure to nicotinamide 
and resveratrol, an inhibitor and an inducer of sirtuin 1 activity, respectively, 
was performed to evaluate the role of sirtuin 1 in H2A.Z levels. In addition, PLA 
was performed to assess whether epigenetic drugs regulate sirtuin 1 and 
H2A.Z interaction.  
 Treatment with TSA alone and combined with DAC led to an increase 
of H2AFZ transcript levels, although with a concomitant decrease in protein 
levels. Conversely, SIRT1 transcript and protein levels increased after drug 
exposure. ChIP revealed an increase of activation marks within the TSS region 
for both genes. Remarkably, after inhibition of sirtuin 1, H2A.Z levels increased 
dramatically, whereas induction of sirtuin 1 led to an abrupt decrease in H2A.Z 
levels. Finally, PLA assay results showed that epigenetic modulating drugs 
favored the interaction between sirtuin 1 and H2A.Z. 
 Although epigenetic drugs are able to regulate both H2AFZ and SIRT1 
transcription levels, the lack of correlation between mRNA and protein levels for 
H2AZ suggest the involvement of a post-translational mechanism. Indeed, 
sirtuin 1 has the ability to degrade H2A.Z, as previously reported for 
cardiomyocytes. Thus, H2A.Z protein levels are indirectly regulated by 
epigenetic drugs, probably through SIRT1 upregulation. In primary PCa, 
overexpression of H2AFZ and downregulation of SIRT1 validate both genes as 
targets of epigenetic treatment. 
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I - INTRODUCTION 
Chromatin is the physiological template of human genome. Its basic unit – the 
nucleosome core particle (Figure 1) – consists of 146 DNA base pairs organized around an 
octamer consisting of two copies of each highly conserved core histone protein – H2A, 
H2B, H3 and H4 [1].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Schematic representation of a nucleosome (Purves et al., 1997 [2]).  
 
Dynamic modulation of chromatin structure (chromatin remodeling), is a key 
component in the regulation of gene expression, DNA replication and repair and 
chromosome condensation and segregation [3]. Disruption of these processes is intimately 
associated with human diseases, including cancer. Hence, the comprehension of 
mechanisms that tightly regulate gene expression in cancer, such as the epigenetic 
mechanisms, not only allows the development of better diagnostic and prognostic markers, 
but most important, the development of therapeutic approaches that might contribute for 
cancer abolition [4].  
Particularly, information regarding the role of histone variants in prostate neoplasm 
is rather poorly understood, as well as the effects of epigenetic treatment with histone 
deacetylases inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi) in 
chromatin remodeling and histone variants deposition.  
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II – STATE OF THE ART 
1. Epigenetics 
 The concept of epigenetics was firstly introduced by Conrad Waddington, who 
defined epigenetic as “the branch of biology which studies the casual interactions between 
genes and their products which bring the phenotype into being” [5, 6]. But the original 
definition has been changed all over the years, being nowadays defined as “the study of 
changes in gene function that are mitotically and/or meiotically heritable and that do not 
entail a change in DNA sequence” [7, 8]. The epigenetic mechanisms that are responsible 
for chromatin remodeling can be divided into four different groups: DNA methylation, 
covalent histone modifications or posttranslational modifications of histones, non-covalent 
modifications of histones, such as incorporation of non-canonical histones and nucleosome 
remodeling, and non-coding RNAs, such as microRNAs [5].   
 
2. Epigenetic mechanisms and their deregulation in cancer 
2.1 DNA methylation 
 The methylation of DNA is probably the most studied epigenetic mechanism. This 
type of modification plays an important role in gene expression regulation, since it 
provides a stable gene silencing. In mammals, this covalent modification of DNA usually 
occurs at cytosines followed by guanine, known as CpG dinucleotides [9]. Interestingly, 
CpG dinucleotides are not evenly distributed in the genome, but, instead they are mostly 
found in „CpG islands‟, which occupy around 60% of human gene promoters, and in 
regions of large repetitive sequences [10]. 
In one hand, whilst most of the CpG sites in genome are methylated, the majority of 
CpG islands usually remain unmethylated during development and in differentiated tissues 
[11]. However, some CpG island promoters become methylated during development, 
resulting in long term transcriptional silencing, such as in X-chromossome (X-
chromossome inactivation) and in imprinted genes [9]. On the other hand, CpG 
dinucleotides that are found in repetitive sequences genome are heavily methylated, in 
II – STATE OF THE ART 
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order to inhibit chromosomal instability, since non-coding DNA and transposable DNA 
elements are silenced [11]. 
The mechanism of methylation of DNA is well established (Figure 2). The reaction 
is catalysed by DNA methyltransferases (DNMTs) and involves the use of a cosubstract, S-
adenosyl-methionine (SAM), which functions as the donor of the methyl (-CH3) group. 
This reaction culminates in the formation of a new DNA base, 5-methylcytosine, which is 
nothing more than a cytosine methylated in the carbon 5 [12, 13].  
 
Figure 2 – Mechanism of cytosine methylation: reaction catalysed by DNMTs, represented as  ES, 
using SAM as the methyl donor group (Gabbara et al., 1995 [14]). 
 
Usually, a cancer epigenome is characterized by global hypomethylation and site-
specific CpG island promoter hypermethylation, being both events important in 
carcinogenesis [4]. 
DNA hypomethylation occurs in several sites of genome, such as repetitive 
elements, retrotransposons and gene deserts, leading to genomic instability, due to 
chromosomal rearrangements and retrotransposons translocation to other genomic areas 
[15, 16]. Simultaneously, another consequence of hypomethylation, is loss of imprinting. 
IGF2 gene is an example where loss of imprinting results in the biallelic expression of this 
important growth factor [17]. 
Similarly, while there is a general hypomethylation on genome, there is a site 
specific hypermethylation that contributes to tumor formation, since it leads to tumor 
suppressor gene silencing, thus serving as the second event of tumor initiation in the 
Knudson‟s two-hit model [4]. 
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2.2 Post-translational modifications of histones: the histone code 
Histones are among the slowest evolving proteins known and they are a major 
component of chromatin, the protein–DNA complex fundamental to genome packaging, 
function, and regulation. Histone proteins contain a globular C-terminal domain and a N-
terminal tail, being the latter very susceptible to posttranslational modifications (PTMs). 
This is due to the nature of the aminoacids sequence of histones, since there are several 
sites where they can undergo covalent modifications [18]. More than 60 residues have been 
reposted to harbour PTMs, specifically lysine (Figure 3) [19]. Even though the most 
understood PTMs are acetylation and methylation, other covalent transformations might 
occur such as phosphorylation, ubiquitylation and sumoylation. Alteration of the pattern of 
histone modifications controls important cellular processes, such as transcription, 
replication and DNA repair [18]. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3 – Most frequent covalent modifications in human histones H3 and H4 (adapted from 
Richards et al., 2009 [20]) 
 
As previously mentioned, an important covalent modification of histones is 
acetylation, modulating chromatin structure and nucleosome packing, exposing or hiding  
specific genes [21]. Since histones contain large amounts of basic amino acids (lysine and 
arginine), acetylation neutralizes the abundance of positive charges, decreasing histone 
affinity for the phosphate backbone of DNA [18, 21]. In general, histone acetylation results 
in charge neutralization and separation of DNA from the histones, allowing nucleossomal 
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DNA to become more accessible to transcription factors. Hence, histone hyperacetylation 
has been correlated to transcriptionally active regions of the genome, whereas silent 
regions are hypoacetylated (Figure 4) [18, 22]. The dynamic and reversible equilibrium 
between acetylated and deacetylated states of histones are regulated by two main protein 
groups: histone acetyltransferases (HATs) and histone deacetylases (HDACs). 
Methylation is a PTM commonly found on histones and, as the acetylation, this 
type of histone modification has a significant role in chromatin remodeling. Namely, 
methylation may be a mechanism to prevent acetylation on lysine residues [23]. The 
enzymes responsible for these modifications are histones methyltransferases (HMTs) and 
its effect is reversed by histones demethylases (HDMs), recently discovered [24, 25]. As 
same as DNMTs, HMTs uses SAM as the methyl group donor, and, contrasting with 
histone acetyltransferases, histones methyltransferases exhibit higher substract specificity 
[24]. 
Unlike acetylation, which is associated with gene transcription activation, 
methylation of histones might lead to activation or repression of specific genes depending 
on the specific residue. For instance, trimethylation of lysine 4 (H3K4me3) and 
methylation of lysine 36 and lysine 79 on histone 3 (H3K36me and H3K79me) are found 
in the promoters of transcriptionally active genes. However, methylation of lysine 20 of 
histone 4 (H4K20me) and trimethylation of lysine 9 and lysine 27 on histone 3 (H3K9me3 
and H3K27me3, respectively) are enriched in promoters of transcriptionally silenced 
genes. In fact, the latter two histone marks are both associated to gene silencing in 
mammalian cells [18]. 
Noticeably, the equilibrium between HMTs and HDMs has an important role in the 
overall histone methylation profile. In fact, the equilibrium verified in a normal 
mammalian cell, is disrupted during disease [26]. 
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Figure 4 – Schematic representation of how histone acetylation works with DNA methylation in 
order to repress or activate transcription (acetylation indicated as the tails in the nucleosomes and 
methylation represented by the circles in DNA strand – red indicates an hypermethylated state, 
while white indicates a normal or hypomethylated state) (adapted from Rodenhiser et al., 2006 
[26]). 
 
2.3 Histones variants and nucleosomal repositioning 
In most organisms, there are multiple copies of the histone genes encoding for the 
major histone proteins. These genes are highly similar in sequence, expressed primarily 
during the S phase of the cell cycle and codify for the bulk of the cellular histones. Whilst 
histones are among the more conserved proteins known, there are nonallelic variants of the 
major histones that might have significant differences in primary sequence. Some variants 
have distinct biophysical characteristics that are thought to alter the properties of 
nucleosomes, while others are localized in specific regions of the genome. Additionally, 
while canonical histones genes are expressed only during the S phase of the cell cycle, 
variant histone genes, or non-canonical histone genes, are expressed through whole cell 
cycle [27-29].   
Some variants replace with the canonical histones during development and 
differentiation, and are therefore referred to as replacement histones [30]. This replacement 
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often results in the variants becoming the predominant species in the differentiated cells 
[31, 32]. These observations have led to the suggestion that the histone variants have 
specialized functions regulating chromatin dynamics, as displayed in Figure 5.  
 
Figure 5 – Representative scheme of canonical and non-canonical histones, most relevant and 
well-established sites for lysine methylation and serine phosphorilation (red flags – methylated 
lysines; green circles – phosporilated serines). The specialized functions purposed for histone 
variants are as well indicated (Sarma et al., 2005 [29]). 
 
 Some specific cases, such as H2A.Z and H3.3, histones variants of H2A and H3, 
respectively, are enriched in promoters of active genes and they might mediate nucleosome 
stability. In addition, H2A.Z can be inserted in nucleosomes in order to prevent DNA 
methylation, thus regulating gene activity [33, 34].  
Regarding variant nucleosomes, one of the most relevant structural occurrences is 
that these nucleosomes have changes on the exposed surface, when compared with 
canonical nucleosomes. MacroH2A (mH2A) has an extensive C-terminal tail that probably 
extends away from the nucleosome and imparts an asymmetrical structure to the variant 
nucleosome which is important for transcriptional repression [35]. 
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Although the overall structure of H2A.Z nucleosomes is similar to the major H2A 
structure, two of the most interesting differences are the presence of an extended acidic 
patch on the nucleosome surface and a novel divalent cation-binding pocket. These 
changes alter protein/nucleosome and nucleosome/nucleosome interactions, as well as the 
higher-order folding of the chromatin, and are important for H2A.Z function during 
development [36]. 
Using FRET assays was possible to observe that the overall binding of the 
H2A.Z/H2B dimer to the H3/H4 tetramer is somewhat stable [37]. Recent data propose 
that the CenH3/H4 tetramer is more dense and rigid than an H3/H4 tetramer and may also 
be more stable [38]. Indeed it is possible that the additional rigidity might help to resist the 
microtubule pulling forces at the centromere during mitosis, or might aid in the assembly 
of kinetochore proteins. Likewise, the mH2A nucleosomes may also be more stable, 
though additional biophysical studies will be required to fully understand the differences 
between the variant and major histone subtypes [39]. Also, the in vivo consequences of a 
more stable variant nucleosome scattered among the canonical nucleosomes are difficult to 
predict. 
In contrast to the other variant nucleosomes, the H2ABbd nucleosome structure 
may be weaker. In the absence of DNA it is unable to form a stable histone octamer, and 
the H2ABbd nucleosome organizes only 118 bp of DNA rather than the 147 bp around the 
histone core [40]. While these nucleosomes are not very mobile, they are less stable and 
more accessible to transcription factors [40]. Therefore, it is likely that the structural 
alterations in the H2A-Bbd nucleosome lead to a weaker nucleosome structure that 
facilitates gene activation. 
 
2.4 Sirtuin 1 and H2A.Z: from the connection to cancer to their putative 
interaction 
2.4.1 The role of H2A.Z in carcinogenesis  
The variant H2A.Z is highly conserved from yeast to man, since 90% of its primary 
sequence is preserved between different species and it shows only 60% homology with 
H2A [41]. H2A.Z is found in approximately 10% of mammalian and chicken nucleosomes, 
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participating in different biological processes such as DNA replication, chromosome 
segregation, heterochromatin condensation and gene transcription [42, 43].  
However, the mechanism by which H2A.Z affects chromatin stability is still not 
fully understood. In fact, different studies reported distinct and controversial conclusions: 
some claim that H2A.Z nucleosomes are more stable [44], while others have observed that 
H2A.Z incorporation destabilizes nucleosome core particles [45]. 
A possible role for H2A.Z in cancer development was first reported by genome 
wide gene expression profiling by Dunican et al., reporting overexpression of H2A.Z in 
microsatellite instable sporadic colorectal tumors [31]. Later, Zucchi et al. found that this 
histone variant was also overexpressed in the latest stages of breast cancer [46]. 
Rhodes et al. have found that 69 genes were overexpressed in undifferentiated 
cancers relative to well differentiated cancers, being H2AFZ one of those genes. Since 
H2A.Z plays a role in chromatin remodeling and in a broad spectrum of transcriptional 
regulations, it has been suggested that H2AFZ might play a critical role in maintaining the 
undifferentiated cellular state of high-grade cancers [47]. 
In fact, the best characterized cancer model regarding H2A.Z role in carcinogenesis 
is breast cancer. Hua et al. described that H2A.Z overexpression and lymph nodes 
metastasis were tightly correlated in primary breast tumors [48]. More recently, it has been 
shown that, not only H2A.Z is important in the regulation of ERα-dependent transcription 
and estrogen-specific cell proliferation, but also that H2A.Z expression promoted cellular 
proliferation even when estrogen levels are low and during tamoxifen treatment (the pro-
proliferative effects of H2A.Z overrides the toxic effects of tamoxifen) [49].  
The combination between H2A.Z expression and short overall patient survival 
suggested that this histone variant might be a biomarker not only of tumor aggressiveness, 
but, eventually, a cause of cancer phenotype [50].  
Additionally, it was already proposed the H2A.Z might be an important indirect 
target for breast cancer therapy, through c-Myc regulation, which is known as an activator 
of H2A.Z expression (Figure 6) [51]. 
 
 
 
 
 
II – STATE OF THE ART 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Model 
of functional 
cooperation between H2A.Z and c-Myc in breast cancer. Upregulation of both proteins, leads to 
downregulation of TP53 and CDKN1A and upregulation of estrogen target genes and transcription 
factors (adapted from Rangasamy et al., 2010 [51]). 
 
2.4.2 The dubious role of sirtuin 1  
 As previously mentioned, the equilibrium between the acetylated and deacetylated 
form of histones is tightly maintained by HATs and HDACs, respectively. However, 
during carcinogenesis, the action of these enzymes, mostly HDACs, are extremely altered 
[52].  
 HDACs are a group of 18 proteins which are divided into 5 different classes 
according to their homology (Figure 7) [53]. Class III HDACs, which entails sirtuins, are 
unrelated to the other classes, since they are dependent of NAD
+
, and not Zn
2+ 
ion like the 
others HDAC classes, being present in the nucleus (sirtuin 1, 6 and 7), cytoplasm (sirtuin 
1) or mitochondria (sirtuin 3, 4 and 5) [54, 55]. Moreover, this specific HDAC class is not 
regulated by HDACi that block the activity of the other HDACs, such as trichostatin A 
(TSA) [56]. Instead, sirtuin 1 is inhibited by nicotinamide (NIC) [57] and its activity is 
enhanced by resveratrol (RES) [58]. 
 Noticeable, several studies have suggested that some members of the HDAC class 
have a critical role in cancer. Interestingly, sirtuin 1, the most studied member of class III 
HDAC, has been reported as being critical in the neoplastic transformation. However, the 
results are quite controversial [59]. Some studies indicated SIRT1 as an oncogene, 
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reporting its importance in p53 deacetylation, which ultimately leads to its inactivation 
[60]. Moreover, SIRT1 has been found overexpressed in several cancer models, such as 
acute myeloid leukaemia [61] and primary colon cancer [62]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Representative scheme of histone deacetylases classes, cellular location and implication 
in cancer (Di Marcotullio et al, 2011 [63]. 
 
Contrarily, others studies refer SIRT1 as an important tumor suppressor gene, being 
recently described as a haploinsufficient tumor suppressor, and has been found to be 
underxpressed in glioblastoma, bladder and ovarian cancers [64]. Interestingly, in prostate 
cancer (PCa) SIRT1 has been reported both as being over and under expressed [64, 65]. 
Thus, it is yet unclear whether SIRT1 acts as a tumor suppressor gene or an oncogene in 
this neoplasm. 
 
2.4.3 Sirtuin 1 marks H2A.Z for degradation 
 Interestingly, an interaction between sirtuin 1 and the histone variant H2A.Z has 
been reported, that ultimately lead to degradation of the latter (Figure 8). Specifically, 
Chen et al. have found that sirtuin 1 deacetylated lysine 15 (Lys-15) of H2A.Z in 
cardiomyocytes, marking it for ubiquitylation. Hence, two specific residues – lysine 115 
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(Lys-115) and lysine 121 (Lys-121) – become ubiquitylated, being consequently degraded 
via an ubiquitin/proteasome-dependent pathway [66]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Remarkably, this event was only reported once and its confirmation in cancer 
models remains unknown. Nevertheless, if this mechanism is proven in cancer cells, this 
would support SIRT1 as a tumor suppressor gene. 
 
3. Prostate 
Prostate is a gland about the size of a walnut and with a conical shape. Regarding 
its location, it is situated in the pelvic cavity, below the lower part of the symphysis pubis, 
above the superior fascia of the urogenital diaphragm, and in front of the rectum, through 
which it might be clearly felt, especially when enlarged [67]. The prostate is a gland 
belonging to the male reproductive system, being responsible for a hydrolytic secretion 
that constitutes about half the volume of the seminal fluid [68]. 
 
 
 Sirtuin 1 
 H2A.Z 
 AcLys15  H2A.Z 
 
Lys15 
 H2A.Z 
 UbLys115 
UbLys121 
Ubiquitylation 
Deacetylation 
 H2A.Z 
 Lys15 
 
 H2A.Z 
 UbLys115 
UbLys121 
Degradation 
Figure 8 – Simplified representation of H2A.Z degradation via ubiquitin/proteasome-dependent 
pathway, initiated by sirtuin 1. 
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Although the concept of prostate anatomy has changed throughout the years, 
McNeal established the current and widely accepted division of prostate. Hence, McNeal 
definied that prostate is divided into four distinct zones: peripheral zone, central zone, 
transition zone and anterior fibromuscular stroma (Figure 9) [69, 70]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – Anatomy of normal prostate as described by McNeal (McNeal, 1980 [70]). 
 
The peripheral zone includes all the prostatic glandular tissue at the apex as well as 
all of the tissue located posteriorly near the capsule. Interestingly, carcinoma, chronic 
prostatitis and postinflammatory atrophy are more probable to happen in this prostate zone 
than in the other three zones. The transition zone, which entails two similar portions of 
glandular tissue lateral to the urethra in the midgland, is where is observed the 
development of benign prostate hyperplasia (BPH) and, not that often, adenocarcinoma 
[71]. 
In addition to these different four zones, the prostate is involved by a capsule. In 
fact, the use of the term „capsule‟ to define the fibrous layer  that embraces the prostate, 
separating prostate stroma from extraprostatic fat fat tissue, is not truly correct. Despite the 
controversy, this terminology is still used until today [72]. 
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3.1 From prostatic intraepithelial neoplasia (PIN) to PCa 
 Some studies concerning the histopathological evaluation of PCa tissue have 
conducted to the identification of a specific abnormality that is known to be the primary 
precursor lesion that might culminate in cancer [73]. Prostatic intraepithelial neoplasia, 
commonly known as PIN, is characterized as a continuum between low-grade and high-
grade forms, with high-grade PIN being the immediate precursor of early invasive PCa 
[73]. 
 The classification of high-grade PIN neoplasia as the precursor of cancer was 
achieved due to a different amount of evidences that support that idea. The location [74], 
appearance [75], chromosomal abnormalities [76-78], cell architecture [79] and 
differentiation markers [80, 81] are evidences pointing towards the notion that PIN lesions 
precedes PCa. Interestingly, PIN lesions do not produce high levels of prostate-specific 
antigen (PSA), thus not being identified in PSA screening test done in blood serum, but 
only in prostate biopsy samples [80]. 
 A very relevant aspect of PIN lesions is their accurate identification by microscopy, 
when compared with other prostate pathological conditions, such as BPH and atypical 
adenomatous hyperplasia, which are not believed to be precursor states of PCa. In 
opposition, the lesion designated as proliferative inflammatory atrophy has been proposed 
as the precursor of PIN lesions [82]. 
 
3.2 Epidemiology of PCa: incidence, mortality and risk factors 
 PCa is the second most frequent neoplasia between male population worldwide 
(13.6% of the total), being only surpassed by lung cancer [83], and the number one 
neoplasia in the male population in developed countries (72.1% of the total cases of PCa 
are observed in developed countries) (Figure 10). Considering de overall population, male 
and female population, PCa is the fifth most frequent neoplasia in the world. In Portugal, 
PCa is the form of cancer with highest incidence between male population [83]. 
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Figure 10 – Statistics concerning prostate cancer incidence: A – worldwide incidence of PCa; B – 
incidence of cancer in Portugal, showing PCa is the most frequent neoplasia; C – incidence of 
cancer worldwide, showing that PCa is only surpassed by lung cancer as the most frequent 
neoplasia (Globocan, 2010 [84]). 
 
Not only there are differences between geographic areas affected by PCa, but there 
are also some changes which occurred throughout the years [85].  In United States of 
America, even though rates of PCa were stabilized until the 1980s, after the introduction of 
PSA screening, the rates of incidence of PCa increased 85% between 1987 and 1992 and, 
despite some subtle differences, the rates fairly remained stable [86].  
That sudden increase in the number of PCa cases is mostly due to the introduction 
of serum PSA evaluation, which was described as the first method in the detection of 
prostate adenocarcinoma. Interestingly, after that, the stabilization of incidence rates 
occurred as a consequence of that new screening test, which possibly detected most of the 
 
A 
B C 
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latent tumors in the population submitted to this evaluation [87]. It is important to mention 
that, despite the fact that the tendency observed in United States of America is verified in 
several countries, in Europe, the rates of PCa incidence are still increasing [83]. 
 
 Regarding mortality, PCa is the sixth most mortal neoplasia among men, being 
responsible for 6.1% of cancer related deaths, excluding non-melanoma skin cancer. 
Contrarily to incidence rates, mortality rates have only changed slightly throughout the 
years [86]. The difference verified through the time can be explained by PSA screening, 
which, in one hand, may have led to an initial increase of mortality rates due to wrong 
death explanation (although deaths were attributed to PCa disease, in fact, people died 
from co-morbid conditions, such as cardiovascular disease or other neoplasm), and, on the 
other hand, the decreased observed in recent years may be due to an early diagnosis of the 
disease and hence a therapy applied on early stages of the neoplasia [87]. 
 
 The risks for development of PCa are still very controversial, but three distinct risk 
factors are well established: increasing age, ethnicity and heredity. In fact, PCa is a disease 
directly related with aging, since incidence increases exponentially with age, being the 
peak of incidence on ages between 72 and 74 years [88]. 
Regarding ethnicity, African Americans have the highest rates of PCa incidence 
and mortality, being followed by Caucasians, Hispanics and, finally, Asians and Pacific 
Islanders [89].  
3.3 Histopathological granding and staging of PCa 
Noticeably, the most prevalent form of PCa is adenocarminoma, accounting for 
about 95% of prostatic neoplasms. Actually, this neoplasia is silent, without specific 
symptoms, despite resembling some characteristics of BHP. Having that, and since the 
diagnosis of PCa is usually done in advanced stages, there is a need to evaluate tumor 
grading and staging [90]. 
The histologic grading by Gleason score is considered the strongest prognostic 
factor of patient‟s time to progression and the tumor is graded from 1 to 5 regarding only 
the architectural appearance under low magnification (Figure 11) [91]. On one hand, well 
differentiated PCa is characterized by a proliferation of microacinar structures lined by 
prostatic luminal cells without an accompanying basal cell layer and is scored from 1 to 2, 
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being considered the lowest grade of Gleason system. On the other hand, a solid pattern 
with central necrosis or infiltrating individual cells is considered the highest grade of 
Gleason system and is scored with 5 [92].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 – Gleason score for histopathological grading of PCa, considering that differentiation 
decreases from 1 to 5 (adapted from Epstein et al, 2011 [93]). 
 
However, considering the PCa heterogeneity, with two or more grades in the same 
tumor sample, Gleason chose to evaluate the prostatic neoplasm incorporating both 
primary and secondary grade into the system, being the first the most prevalent one. 
Hence, the Gleason scores possibilities range from 2 (1 + 1) to 10 (5 + 5) [94]. 
Concerning the staging for prostatic adenocarcinoma, in the early 1950s was 
implemented the staging system which is considered today [95]. It concerns the extent of 
primary tumor (T), regional lymph nodes status (N) and distant metastases (M). 
 
 
Legend: 
1 – closely packed, small 
and uniform glands; 
2 – more stroma between 
glands, that are round and 
oval, with minimal 
invasion of non-neoplastic 
tissue; 
3 – irregular sized glands 
with angular shape and 
more infiltrative margins; 
4 – fused, cribiform and 
poorly defined glands; 
5 – occasional gland 
formation . 
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Table 1 – Overview of International Union Against Cancer (UICC) TNM/pTNM staging system 
for PCa (adapted from Edge et al., 2010 [96]) 
Stage                                           Primary tumor, clinical (T) 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
T1 Clinically inapparent tumor not palpable or visible by imaging 
 T1a Tumor incidental histologic finding in 5% or less of tissue resected 
 T1b Tumor incidental histologic finding in more than 5% of tissue resected 
 T1c Tumor identified by needle biopsy 
T2 Tumor confined within the prostate 
 T2a Tumor involves half of one lobe or less 
 T2b Tumor involves more than half of one lobe but not both 
 T2c Tumor involves both lobes 
T3 Tumor extends through the prostate capsule 
 T3a Extracapsular extension (unilateral or bilateral) 
 T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than seminal vesicle(s) 
Primary tumor, pathologic (pT) 
pT2
c
 Organ confined 
 pT2a Unilateral, involving half of one lobe or less 
 pT2b Unilateral, involving more than half of one lobe but not both lobes 
 pT2c Bilateral 
pT3 Extraprostatic extension 
 pT3a Extraprostatic extension 
 pT3b Seminal vesicle invasion 
pT4 Invasion of bladder, rectum 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 Noregional lymph nodes metastasis 
N1 Metatasis in regional lymph node or nodes 
Distant metastases (M) 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 M1a Non-regional lymph node(s) 
 M1b Bone(s) 
 M1c Other site(s) 
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This classification allows a more precise stratification of patients into groups with 
distinct prognosis.  
Regarding metastases, although these might occur in several areas, like kidney, 
breast, liver and brain, they are mainly observed into pelvic lymph nodes, bones and lungs 
[97]. Remarkably, the most used PCa cell lines, an in vitro model to study and understand 
PCa, results from PCa metastasis. For instance, LNCaP, an androgen-sensitive PCa cell 
line, is derived from the left supraclavicular lymph node metastasis, and PC-3, an 
androgen-insensitive PCa cell line, is derived from bone metastasis [98]. 
 
3.4 Prostate cancer treatment 
 The therapeutic decision for PCa is currently based in a multidisciplinary approach 
and takes into account the TNM classification and Gleason Score of the tumor, 
preoperative serum PSA level and patient‟s age, life expectancy, comorbidity and quality 
of life and it is based. 
 
 3.4.1 Treatment of clinically localized, early-stage disease 
Two firstly considered therapeutic options are watchful waiting (WW) and active 
surveillance (AS), being subtly different. In the WW approach there is a setback in active 
treatment in patients who are not candidates for an aggressive local therapy, until a patient 
develops evidence of symptomatic disease progression, at which point androgen-
deprivation treatment in initiated [99]. On the other hand, AS is more suitable for those 
patients who a curative option might be also offered. The patients with low risk of PCa that 
fulfill the requirements for AS therapy (Table 2) are initially not treated, but are followed 
and treated with a curative intent if progression occurs during follow-up, with regular 
serum PSA evaluations and periodic prostatic biopsies [100].  
The removal of the whole prostate gland and the seminal vesicles – radical 
prostatectomy – is the only treatment that revealed a cancer-specific survival higher than 
WW or AS [101]. Nowadays, this surgical approach is so polished that it offers high rates 
of cure and concomitant decreased morbidities, such as erectile dysfunction and urinary 
incontinence [96]. 
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Table 2 – Eligibility criteria for potential AS patients (adapted from Heidenreich et al., 2011 [102]) 
Active 
Surveillance 
Approach 
Criteria 
Clinically confined prostate cancer (T1-T2) 
Gleason score ≤ 6 
Three or fewer biopsies involved with cancer 
≤ 50% of each biopsy involved with cancer 
PSA ≤ 10ng/mL 
 
Alternatively to radical prostatectomy, external-beam radiation therapy [103] and 
transperineal low-dose rate brachytherapy [104] may be offered. In fact, both approaches 
have shown high rates of disease-free survival [102]. 
 
3.4.2 Treatment of advanced, castration-resistant prostate cancer 
 While for clinically localized, early-stage disease the treatment is often curative, the 
same panorama is not evident for advanced, castration-resistant PCa [83]. 
 Androgen deprivation therapy is the first-line treatment for patients with metastatic 
disease and is based in chemical castration (luteinizing hormone-releasing hormone drugs) 
or surgical castration (orchiectomy) [105]. However, the most part of the patients develop 
progressive disease after a median response to therapy of 18-30 months, which culminates 
in castration resistant PCa [106]. This stage is ultimately untreatable, even after therapy 
with the most effective chemotherapeutic agents, such as docetaxel, estramustine or 
prednisone [107, 108]. In addition, many patients develop metastases, usually bone 
metastases, responsible for excruciating pain that is not mitigated with chemotherapy 
[109]. Once spread, PCa is not curable and all therapy currently available is merely 
palliative.  
 
3.5 Epigenetic alterations in prostate cancer 
Although epigenetic mechanisms have a very important role in gene expression 
regulation in normal mammalian cells, in neoplasic cells, the normal patterns are altered. 
Indeed, the so called „epimutations‟, alongside with genetic alterations, greatly contributes 
to malignant transformation.  
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Remarkably, PCa, as well as other tumor models, is the perfect paradigm of 
epigenetic catastrophe, since deregulation of a wide array of epigenetic mechanisms have 
been found  in this disease, promoting cancer development and progression [5].  
 
3.5.1 The DNA methylation profile in prostate cancer 
Hypermethylation of DNA is one of most studied epigenetic deregulation in PCa, 
leading to gene silencing and loss of gene function, contributing to tumor initiation, 
progression and metastasis. GSTP1 gene is probably the gene which promoter is more 
often reported as hypermethylated in PCa, leading to transcriptional silencing [110]. Being 
a very important enzyme in cellular metabolism, glutathione S-transferase P, encoded by 
GSTP1, is responsible for the elimination of reactive chemical species and protects the cell 
DNA from damage [111]. The loss of expression of GSTP1 is found in PCa tissue and in 
tissues with PIN lesions, but not in normal prostate tissue or tissue from benign prostate 
hyperplasia [110, 112-114]. 
 Another gene that is usually hypermethylated in PCa is the E-cadherin gene 
(CDH1) and loss of its transcriptional activity leads to transition from adenoma to 
carcinoma and acquisition of metastasic ability [115]. Actually, loss of E-cadherin 
expression have been linked to higher tumor grade [116]. As same as for GSTP1, CDH1 is 
transcriptionally silenced due to hypermethylation of its promoter and treatment with 
demethylating agents, such as 5-aza-2‟-deoxycytidine (DAC), have been reported to 
restore expression of E-cadherin levels [117]. 
 Additionally, the androgen receptor (AR), activated by androgens, have been also 
reported to be regulated by DNA methylation in PCa. Although PCa is androgen dependent 
in its initial stages, it becomes androgen independent, due to gene promoter silencing. In 
AR-negative PCa cell lines, such as DU145, which promoter of AR gene is 
hypermethylated, in constrast with AR-positive PCa cell line LNCaP, gene re-expression 
has been achieved after treatment with DAC [118]. 
 Furthermore, CD44 is a gene which promoter is also hypermethylated in PCa. The 
glycoprotein codified by this gene is relevant for cell matrix adhesion, thus having an 
important role in cancer progression and metastasis [119].  Likewise, APC gene promoter 
was found to be hypermethylated in PCa, being a predictor of PCa progression and an 
important biomarker for prognosis evaluation [120]. Thus, currently more than 50 cancer-
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related genes linked to important cellular pathways have been already found to be 
hypermethylated in PCa and therefore playing a critical role in neoplastic transformation 
[121].  
 
 3.5.2 Histone marks pattern 
Focusing on global histone modification, there are patterns that predict the risk for 
PCa recurrence. PTMs in histone H3, such as H3K4me2 and H3K18ac, have been 
proposed as biological markers for PCa [122]. In addition, during tumor progression, high 
levels of epigenetic promoter silencing have been observed, resulting in permanent gene-
silencing in neoplastic cells and their progeny [4]. This silencing of tumor suppressor 
genes has been associated with a particular combination of histone marks, such as: 
deacetylation of histones H3 and H4, loss of H3K4me, H3K9me2 and H3K9me3 and gain 
of H3K9me and H3K27me3 [123]. In fact, low levels of two of those marks – AcH3 and 
H3K9me – have been proposed to accurately distinguish between malignant and non-
malignant samples. In addition, recently it was reported that high levels of H3K18Ac and 
H3K4me2 were indicative of a three-fold risk of cancer relapse/recurrence [124]. 
3.5.3 H2A.Z acetylation is fundamental for oncogenes expression in prostate 
cancer 
As previously mentioned, H2A.Z has been associated with the carcinogenic 
process, mostly in breast cancer. Regarding PCa, it has been previously reported a 
significant increase of H2A.Z in castration-resistant LNCaP xenograft model of PCa. In 
fact is has been suggested that in a subset of primary prostate tumors the elevated 
expression of H2A.Z might be indicative of PCa progression to androgen independence 
[125]. 
Noticeable, a recent study evaluated how H2A.Z and its acetylated type interfere 
with transcription of oncogenes in PCa cell lines. In the same study the authors 
demonstrated that AcH2A.Z mutually excluded DNA methylation and H3K27me3, but 
was also tightly associated with active gene transcription. In fact, this posttranslational 
modification of H2A.Z tended to accumulate within the TSS of active genes. In contrast, in 
genes with lower activity during carcinogenesis, such as tumor suppressor genes, H2A.Z 
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deacetylation was mostly prevalent in nucleosomes next to the TSS and correlated with 
lower gene transcription activity [126].  
Furthermore an activation/repression mechanism have been recently established 
(Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 – Model of gene transcription regulation dependent of H2A.Z occupancy in PCa.        
(A) H2A.Z, by some uncertain mechanism, become hypoacetylated or is replaced by the 
deacetylated form of H2A.Z, leading to decreased expression of tumor suppressor gene.              
(B) Surrounding the TSS of oncogenes, after neoplastic transformation, H2A.Z become acetylated 
or it is substituted by its acetylated form, promoting the expression of this genes (Valdés-Mora et 
al., 2012 [126]). 
 
Nevertheless, in PCa the studies concerning H2A.Z are limited and solid 
information is not available yet. 
3.6 Epigenetic modulating drugs and their importance in prostate cancer  
 One of the major features of epigenetic regulation is their reversible potential, a 
characteristic that is not shared by genetic alterations. Hence, this premise appears as an 
attractive for epigenetic treatment. Epigenetic modulating drugs have the capacity to 
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remodel the chromatin leading to re-expression of genes that might be silenced during 
tumor initiation and progression. 
 
3.6.1 DAC and its relevance as DNA methyltransferase inhibitor 
DAC exerts its antineoplasic activity by incorporating itself into newly synthetized 
DNA, during S-phase (Figure 13) [127]. At high doses its cytotoxic activity is due to 
covalent trapping off DNMT into DNA [128]. But, at lower doses, the mechanism is 
slightly different: the anti-oncogenic action results from its capacity to inhibit DNA 
hypermethylation and to reactivate tumor suppressor genes [127, 128]. DAC is 
phosphorylated and then incorporated into DNA, covalently binding to DNMT, acting as 
an irreversible inhibitor of the enzymatic activity of DNMTs [129]. 
 
Figure 13 – Representation of the mechanism of action of 5-aza-2‟-deoxycytidine, which is 
incorporated during DNA synthesis, replacing the standard cytidine (adapted from Fandy et al., 
2009 [130]). 
 
It seems that there is a cascade of biochemical events initiated by promoter DNA 
methylation that involves initial DNA binding proteins, which attracts HDACs and HMTs, 
modifying histones into a silenced chromatin state, thus creating a silencing loop. Hence, 
DAC might interrupt this loop, since it induces hypomethylation and reverses the silence 
histone code at tumor suppressor genes loci [131, 132]. Actually, the effects of this drug on 
the histone code are not confined to genes showing silencing by promoter-associated 
methylation [133]. DAC  also leads to enhanced acetylation of histones H3 e H4 at the 
promoter regions [134].  
Although some studies regarding PCa therapy have been performed, it is important 
to mention that it is not well understood how and in which genes does DAC acts. Indeed, 
some experiments were performed to access the effect of this molecule in preventing gene 
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promoter methylation and it has been showed that DAC, induced re-expression of AR, 
estrogen receptor, progesterone receptor, E-cadehrin, CD44 and several genes of Y-
chromosome, despite not preventing DNMT and BCL2 expression[135-137].  
3.6.2 Trichostatin A (TSA) and its potencial as HDACi 
HDAC are complexes that enzymatically remove the acetyl group from lysine 
residues of the amino-terminal tails of histones, thus maintaining chromatin in a 
transcriptionally inactive state. This transcriptional blockade can be overcome by HDACi 
(Figure 14).  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 14 – TSA inhibits the activity of HDAC, allowing the histones to remain acetylated, 
bringing the chromatin into a transcriptional active state (adapted from Nasu, 2008 [138]). 
 
A diversity of agents exhibit HDAC inhibitory activity and may have antitumor 
activity. Amongst the most usual HDACi used are TSA, sodium butyrate, depsipeptide, 
valproic acid, MS-275, SAHA, pyroxamide and phenylbutyrate. TSA was the first 
hydroxamic acid HDACi identified and it is a potent, but reversible, HDAC inhibitor, since 
it binds strongly to the HDAC catalytic site [139] (Figure 15).  
TSA induces cell death and inhibits growth and proliferation of PCa cell line, since 
it inhibits the expression of AR [140, 141], and inhibits ERα-positive breast cancer cells‟ 
growth in vitro and in vivo [142]. TSA enhances acetylation as well as the stability of the 
ERα protein and p300 protein (proteins that may contribute to the treatment of human 
breast cancer) [142].  
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In vitro assays showed that TSA stabilized the site-specific acetylation of lysine 
373 of p53 in LNCaP cells, which increased the basal levels of this proteins, a very well-
known tumor suppressor protein, promoting cells‟ arrest at G1/S, even though not inducing 
apoptosis [143, 144].  
 
Figure 15 – Representation of how TSA interacts with the catalytic site of a HDAC homologue, 
forming a complex and inhibiting the catalytic capacity of the enzyme (Yoshida et al., 2001 [145]). 
 
Furthermore, in vitro experiments revealed that TSA induced hyperacetylation of 
X-ray repair cross-complementing protein 6 (Ku70) which decreases its ability to repair 
drug-induced DNA damage [146]. Interestingly, treatment of DU145 with both TSA and 
DAC has been found to be more effective in restoring functional expression of the AR and 
its downstream targets [146].  
 
 
Currently, the implication of epigenetic deregulation in PCa is already 
acknowledged, either by site-specific DNA hypermethylation or histones‟ posttranslational 
modifications. However, information concerning the role of histone variants in 
carcinogenesis in PCa is rather poorly understood. Moreover, the effects of epigenetic 
treatment with HDACi and DNMTi in chromatin remodeling and histone variants need to 
be clarified. Therefore, there is a need to evaluate the impact of epigenetic modulating 
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drugs in non-canonical histones and nucleosome assembly regulation. In addition, a 
relation between sirtuin 1 and H2A.Z in cancer is yet to be reported, being this putative 
interaction an important mechanism of nucleosome assembly. 
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III – AIMS 
 
 The effect of epigenetic drugs on the transcription of cancer-related genes is well 
known and its effectiveness might allow for the design of novel and alternative therapeutic 
approaches for cancer treatment. Since the carcinogenic role of H2A.Z has been previously 
documented in several tumor models, the main goal of this study was to evaluate the effect 
of epigenetic modulating drugs on the regulation of H2A.Z expression in prostate cancer. 
  
The specific aims of this work were: 
  
 Evaluate mRNA and protein levels of H2AFZ in PCa cells lines after 
exposure to epigenetic modulating drugs; 
 Correlate the previous results with histone post-translational modifications 
of H2AFZ promoter; 
 Assess mRNA and protein levels of SIRT1 in PCa cells lines after exposure 
to epigenetic modulating drugs and correlate them with histone post-
translational modifications of SIRT1 promoter; 
 Determine whether H2A.Z is regulated by sirtuin 1 in PCa cell lines, 
through: 
o Modulation of H2A.Z levels after pharmacological 
inhibition of sirtuin 1; 
o Assess H2A.Z levels after pharmacological activation of 
sirtuin 1; 
 Assess the role of epigenetic modulating drugs regarding its capacity to 
promote physical interaction between sirtuin 1 and H2A.Z; 
 Evaluate H2AFZ and SIRT1 transcript levels in tissue samples and correlate 
the results with standard clinical and pathological parameters.  
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IV - Material and Methods 
1. Cell Culture 
 Three PCa cell lines were selected for subsequent studies to evaluate the impact of 
epigenetic modulating drugs in H2AFZ and SIRT1 transcript and protein levels. The chosen 
cell lines were LNCaP, DU145 and PC-3. PC-3 and LNCaP were acquire from the German 
Resource Centre for Biological Material (DSMZ, Braunschweig, Germany) and DU145 
cell line was obtained from American Type Culture Collection (ATCC, Lockville, MD, 
USA) and were kindly provided by Prof. Ragnhild A. Lothe from the Department of 
Cancer Prevention at the Institute for Cancer Research, Oslo, Norway. 
 All cell lines were grown in the recommended medium (Table 3), supplemented 
with 10% Fetal Bovine Serum (GIBCO®, Invitrogen, Carlsbad, CA, USA) and 1% 
Penicillin-Streptomycin (GIBCO®, Invitrogen, Carlsbad, CA, USA). Cell lines were 
subcultered using Dissociation Reagent trypLE™ Express (GIBCO®, Invitrogen, 
Carlsbad, CA, USA) to harvest them as many times as necessary to obtain the desired 
number of 75cm
3
 cell culture flasks. 
 
Table 3 – Prostate cancer cell lines features and requirements for growth [147]. 
Cell Line Origin AR Status 
Metastasic 
Potencial 
Culture 
Medium 
LNCaP 
Derived from the 
left 
supraclavicular 
lymph node 
metastasis 
Androgen 
sensible 
Low RPMI 
DU145 
Derived from 
brain metastasis 
Hormono-
refractory 
Moderate MEM 
PC-3 
Derived from 
bone metastasis 
Hormono-
refractory 
High RPMI + F12 
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1.1 Cell lines treatment with epigenetic-modulating drugs 
 The three cell lines were grown and treated with a pharmacological DNMTi, DAC 
(Sigma-Aldrich, Germany), and/or with a pan-inhibitor of HDACs, TSA (Sigma-Aldrich, 
Germany). 
 To prepare the stock solution of DAC at a concentration of 100mM, 10mg of the 
drug were dissolved in 438µL of 50% acetic acid and stored at -80ºC.  Right before the use 
of this drug, the stock solution was diluted in 1x PBS to a final concentration of 10mM. To 
prepare the solution of 1mM TSA, which was the solution used during treatments, the 
5mM TSA solution was diluted with 1x PBS. Finally, both solutions were stored at -20ºC 
during the treatment process. 
  The cell lines were grown until 20 to 30% of confluence was reached in 75cm
3
 cell 
culture flasks. The, medium containing the corresponding drug(s) was added accordingly. 
Culture medium and drug(s) were renewed every day according to the schedule 
represented in Table 4. 
 
Table 4 – Treatment timetable with the epigenetic modulating drugs DAC and/or TSA for three 
PCa cell lines (LNCaP, PC-3 and DU145). 
 Day 1 Day 2 Day 3 Day 4 
Mock 15mL medium 15mL medium 15mL medium Harvest 
1 µM  
DAC 
15mL medium 
+ 
1.5 µL DAC 
(10mM) 
15mL medium 
+ 
1.5 µL DAC 
(10mM) 
15mL medium  
+ 
1.5 µL DAC 
(10mM) 
Harvest 
0.5 µM TSA 
15mL medium 
 
15mL medium 
 
15mL medium 
+ 
7.5 µL TSA (1mM) 
Harvest 
1 µM  
DAC 
+  
0.5 µM TSA 
15mL medium 
+ 
1.5 µL DAC 
(10mM) 
15mL medium 
+ 
1.5 µL DAC 
(10mM) 
15mL medium 
+  
1.5 µL DAC 
(10mM) 
+  
7.5 µL TSA (1mM) 
Harvest 
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 The Mock cells were used as controls as they were submitted to the medium change 
procedure but were not exposed to any drugs. All the treatments were done in triplicate. On 
the last day of treatment, after 72h of exposure to the drug(s), cells were harvested by 
trypsinization and centrifuged. Pellets were washed in 1x PBS. After discarding 1x PBS, 
cells were stored separately for RNA and protein extraction at -80ºC. 
1.2 Cell lines treatment with nicotinamide and resveratrol 
 NIC (Sigma-Aldrich, Germany) was obtained in the solid form and was prepared 
immediately before its use. Thus, 1.221g of NIC were dissolved in 10mL of 1x PBS, in 
order to obtain a solution with a final concentration of 1M. This solution was stored at -
20ºC and the treatment procedure is described in Table 5. 
 
Table 5 - Treatment schedule with NIC, DAC and TSA for three PCa cell lines (LNCaP, PC-3 and 
DU145). 
 Day 1 Day 2 Day 3 Day 4 
Mock 15mL medium 15mL medium 15mL medium Harvest 
20mM 
NIC 
15mL medium 
+ 
300 µL NIC (1M) 
15mL medium 
+ 
300 µL NIC (1M) 
15mL medium  
+ 
300 µL NIC (1M) 
Harvest 
0.5 µM TSA 
+ 
20mM NIC 
15mL medium 
+ 
300 µL NIC (1M) 
15mL medium 
+ 
300 µL NIC (1M) 
15mL medium 
+ 
7.5 µL TSA (1mM) 
+ 
300 µL NIC (1M) 
Harvest 
1 µM  
DAC 
+  
0.5 µM TSA 
+ 
20mM 
NIC 
15mL medium 
+ 
1.5 µL DAC 
(10mM) 
+ 
300 µL NIC (1M) 
15mL medium 
+ 
1.5 µL DAC 
(10mM) 
+ 
300 µL NIC (1M) 
15mL medium 
+  
1.5 µL DAC 
(10mM) 
+  
7.5 µL TSA (1mM) 
+ 
300 µL NIC (1M) 
Harvest 
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 RES (Sigma-Aldrich, Germany) was used since it has been described as an 
activator of sirtuin 1. The 100mM stock solution of RES was prepared dissolving 100mg in 
absolute ethanol and aliquots were stored at -20ºC. Right before its use, the 100mM RES 
solution was diluted with ethanol until a final concentration of 10mM, being this last 
solution the one used along the treatment procedure, as described in Table 6. 
 
Table 6 – Treatment schedule with RES, DAC and TSA for three PCa cell lines (LNCaP, PC-3 and 
DU145). 
 Day 1 Day 2 Day 3 Day 4 
Mock 15mL medium 15mL medium 15mL medium Harvest 
40µM 
RES 
15mL medium 
+ 
60µL RES 
 (10mM) 
15mL medium 
+ 
60µL RES 
 (10mM) 
15mL medium  
+ 
60µL RES 
 (10mM) 
Harvest 
0.5 µM TSA 
+ 
40µM 
RES 
15mL medium 
+ 
60µL RES  
(10mM) 
15mL medium 
+ 
60µL RES 
 (10mM) 
15mL medium 
+ 
7.5 µL TSA (1mM) 
+ 
60µL RES (10mM) 
Harvest 
1 µM  
DAC 
+  
0.5 µM TSA 
+ 
40µM 
RES 
15mL medium 
+ 
1.5 µL DAC 
(10mM) 
+ 
60µL  
RES (10mM) 
15mL medium 
+ 
1.5 µL DAC 
(10mM) 
+ 
60µL  
RES (10mM) 
15mL medium 
+  
1.5 µL DAC 
(10mM) 
+  
7.5 µL TSA (1mM) 
+ 
60µL RES (10mM) 
Harvest 
 
In both cases as previously described the Mock cells were used as controls as they 
were submitted to the medium change procedure but were not exposed to any of the 
selected drugs. All the treatments were done in triplicate. On the last day of treatment, after 
72h of exposure to the drug(s), cells were harvested by trypsinization and centrifuged. 
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Pellets were washed in 1x PBS. After discarding 1x PBS, cells were stored separately for 
RNA and protein extraction at -80ºC. 
 
2. Expression analysis 
2.1 RNA extraction and quantification 
 Total RNA extraction was performed using TRIzol® Reagent (Invitrogen, 
Carlsbad, CA, USA), according to manufacturer‟s instructions. Briefly, cell pellets were 
thawed on ice, 1mL of TRIzol® Reagent was added to each sample and cells were 
homogenized using a syringe. The homogenized samples were incubated for 5 minutes at 
room temperature to allow the complete dissociation of nucleoprotein complexes. After the 
incubation, all content of the tubes was transferred to 1.5mL RNAse-free tubes, 200µL of 
chloroform were added, the tubes vortexed for 15 seconds and incubated at room 
temperature for 3 minutes, followed by a centrifugation for 15 minutes at 10,600rpm, at 
4ºC. Ended the centrifugation, it was possible to distinguish a lower red, phenol-
chloroform phase, an interphase and an upper colorless aqueous phase enriched with RNA. 
Hence, the phase containing the RNA fraction was collected into a fresh RNAse-free tube 
and placed on ice. Afterwards, 500µL of isopropyl alcohol were added, the tubes 
vigorously inverted by hand and placed at room temperature for 10 minutes, to allow the 
RNA precipitation. Then, tubes were centrifuged for 10 minutes at 10,600rpm, at 4ºC, and 
the supernatant was discarded without disturbing the pellet. Finally, 1mL of 75% (v/v) 
ethanol was added to wash the RNA pellets by vortexing, followed by a centrifugation at 
8,400rpm for 10 minutes, at 4ºC. The supernatant was carefully discarded and the RNA 
pellets were air-dried for 15-20 minutes. RNA pellets were eluted in a variable volume of 
RNA Storage Solution (1mM Sodium Citrate, pH 6.4) (Ambion, Applied Biosystems, 
Foster City, CA, USA) according to pellet size and placed on ice for at least 30 minutes 
before evaluation of RNA concentration and quality using a Nano Drop ND-1000 
spectrophotometer (NanoDrop Technologies, USA). RNA was stored at -80ºC until further 
use. 
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2.2 DNAse treatment 
 In order to remove any genomic DNA present in our samples after RNA extraction, 
a treatment with DNase was performed, using TURBO DNA-free™ (Ambion, Applied 
Biosystems, Foster City, CA, USA) according to the protocol suggested by manufacturer. 
In short, 10µg of our previously extracted RNA were aliquoted into fresh-RNAse free 
500µL tubes and DEPC-treated water (MP Biomedicals, OH, USA) was added until a final 
volume of 50µL was reached. Afterwards, 5µL of 10x TURBO DNase I Buffer and 1µL of 
TURBO DNase were added and an incubation of 30 minutes at 37ºC took place. Ended the 
incubation, 5µL of DNase Inactivation Reagent were added, tubes were vigorously mixed, 
incubated at room temperature for 2 minutes and centrifuged at 10,000 x g for 90 seconds. 
Finally, supernatant was carefully removed and stored into fresh, RNAse-free tubes. 
 
2.3 cDNA synthesis 
 For gene expression analysis, cDNA was synthesized by reverse transcription using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, 
USA), according to manufacturer‟s protocol. Hence, and briefly explained, in each 
RNAse-free PCR tube, which were packed on ice, were added 1000ng of template RNA 
(thawed on ice), 1x RT random primers, 1x RT buffer, 1x dNTP mix (4mM), 1µL of 
RNAse inhibitor, 1µL of Multiscribe™ Reverse Transcriptase and DEPC-treated water 
(MP Biomedicals, LLC, OH, USA) to complete a total volume of 20µL. All the 
components were gently mixed and the mixture was incubated at 25ºC for 10 minutes, 
followed by 37ºC for 120 minutes and, finally, 85ºC for 5 minutes. The incubation period 
was performed in a Veriti® Thermal Cycler (Applied Biosystems, Foster City, CA, USA). 
Tubes were chilled on ice and 200µL of DEPC-treated water (MP Biomedicals, OH, USA) 
were used to dilute newly synthetized cDNA. All this procedure was also applied to 
Human Total RNA (Applied Biosystems, Foster City, CA, USA), that was used as a 
positive control for qRT-PCR assay further described. In this case, cDNA was diluted in 
100μL of DEPC-treated water (MP Biomedicals, OH, USA). All samples were stored at -
20ºC until further use. 
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2.4 Quantitative reverse transcriptase PCR (qRT-PCR) 
H2AFZ and SIRT1 transcripts were quantified by real time quantitative PCR. The 
assays were performed using gene expression assays for H2AFZ (Hs01888362_g1, 
Applied Biosystems, Foster City, CA, USA), SIRT1 (Hs01009005_m1, Applied 
Biosystems, Foster City, CA, USA ) and the endogenous control GUSB (Hs99999908_m1, 
Applied Biosystems, Foster City, CA, USA), being the last one used to normalize cDNA 
input. The expression assays were performed separately in 96-well plates in 7500 Real 
Time PCR System (Applied Biosystems, Foster City, CA, USA), according to the 
recommended protocol. 
In brief, in each well 9µL of previously synthesized cDNA, 1µL of TaqMan® Gene 
Expression Assay and 10µL of TaqMan® Universal PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA) were added. PCR conditions were those previously 
defined by manufacturer: 50ºC for 2 minutes, 95ºC for 10 minutes, 45 cycles at 95ºC for 15 
seconds and 60ºC for 1 minute. All cDNA samples were run in triplicate. cDNA 
synthesized from Human Total RNA (Applied Biosystems, Foster City, CA, USA) was 
used to prepare five consecutive cDNA dilutions (dilution factor of 10x) that were used as 
standards on each plate, allowing the construction of a standard curve for relative 
quantification and PCR efficiency assessment. Furthermore, multiple water blanks were 
added to each plate as negative controls. 
The results were analysed using the 7500 Software for 7500 and 7500 Fast Real 
Time PCR Systems version 2.0.6 (Applied Biosystems, Foster City, CA, USA). A run was 
considered valid when the slope of the corresponding standard curve was above -3.60 
(corresponding to a PCR efficiency >90%) and the R
2
 of at least three relevant points 
exceeded 0.98. 
For each sample, the mean quantity of H2AFZ and SIRT1 expression levels were 
normalized against the mean quantity of GUSB expression levels for the corresponding 
sample. This ratio was then multiplied by 1000 for easier tabulation (Target Gene 
Expression Level = (Target Gene Mean Quantity / GUSB Mean Quantity) x 1000). Results 
were further presented as fold variation in comparison to our experimental control (Mock). 
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3. Protein levels analysis 
3.1 Nucleus isolation 
In order to inhibit protein degradation, all the procedure took place at 4ºC. Briefly, 
after harvesting, cells were twice washed in ice-cold 1x PBS, followed by a centrifugation 
at 1,500 x g for 5 minutes. Cell pellet was suspended in Buffer I ( 0.01M Tris-HCl, 0.01M 
NaCl, 0.003M MgCl2, 0.03M sucrose, pH 7 with the addition of 500µL of NP-40 for each 
100mL of Buffer I prepared) and centrifuged at 1,500 x g for 10 minutes. Supernatant was 
promptly disposed and a new wash was performed in Buffer I, followed by a 
centrifugation. After the elimination of supernatant, two consecutive washes were carried 
out in 2mL of Buffer II (for each 100mL of Buffer I were added 1mL of 10mM CaCl2) , 
each of them followed by a centrifugation at 1,500 x g. Finally, the nucleuses were purified 
and nuclear protein extraction was performed. 
 
3.2 Nuclear protein extraction and quantification 
Nuclear protein extraction from purified nucleus was performed using RIPA (Radio 
Immnuno Precipitation Assay) lysis buffer (Santa Cruz Biotechnology Inc., Santa Cruz, 
CA, USA). An appropriated volume of complete RIPA Buffer (1x RIPA lysis Buffer, 1mM 
PMSF solution, 100mM sodium orthovanadate solution and 25x Protease Inhibitor 
Cocktail Solution) was added to the nucleus pellet, followed by vortexing to promote 
nuclear lysis. The lysates were transferred into a tube and incubated on ice for 15 min. 
After incubation, the tubes were centrifuged for 30 minutes at 13,000rpm at 4ºC to pellet 
the cell debris. The supernatant was collected to a new tube and the protein concentration 
was assessed by Qubit® 2.0 Fluorometer (Applied Biosystems, Foster City, CA, USA). 
Protein was stored at -80ºC until further use.  
 
3.3 SDS-PAGE and Western Blot 
 Protein levels of H2A.Z and sirtuin 1 were evaluated by Western Blot using 
specific antibodies. The electrophoretic separation of proteins was performed on a 
polyacrylamide gel. The gel was prepared as described by Laemmli et al.: 12.5% running 
gel [12.5% (w/v) acrylamide/bis-acrylamide solution, 0.375M Tris-HCL pH8.8, 0,1% 
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(w/v) SDS, 0.1% (w/v) APS and 0.04% (v/v) TEMED] and 4% stacking gel [4% (w/v) 
acrylamide/bis-acrylamide solution, 0.062M Tris-HCL pH6.8, 0.1% (w/v) SDS, 0.1% 
(w/v) APS and 0.25% (v/v) TEMED] [148]. Then, protein was suspended in loading buffer 
and denaturated at 95ºC for 5 minutes. The proteins were loaded in the running gel for 
separation and electrophoresis was performed in a drive Mini-Protean 3 Electrophoresis 
System (BioRad, Hercules, CA, USA), in running buffer (0.025M Tris, 0.192M glycine 
and 0.1% SDS, pH8.3) at 120V until the samples reached the bottom of the gel. 
 After their separation, proteins were blotted onto Immobilon®-P Transfer 
Membrane (Millipore, MA, USA). The system was mounted on a transfer unit Mini-
PROTEAN 3 Electrophoresis System (BioRad, Hercules, CA, USA), according to 
manufacturer‟s instructions, and the transfer occurred at 50V at 4ºC for 3 hours in transfer 
buffer [0.025M Tris, 0.192M glycine, 20% (v/v) methanol]. After electroblotting, the 
membranes were incubated in blocking solution [5% (w/v) nonfat dry milk in 0.01M Tris-
buffered saline containing 0.1% (v/v) Tween 20] for at least 1 hour, at room temperature 
with gentle shaking. The membranes were then incubated overnight at 4ºC in primary 
antibody – anti-H2A.Z (#2718, Cell Signaling Technology®, MA, USA) and anti-Sirtuin 1 
(#1104-1, Epitomics®, CA, USA) – diluted 1:1000 in blocking buffer. 
After the incubation with the primary antibody, the membrane was washed with 
Tween-TBS for 10 minutes with vigorous shaking, followed by two washes of 5 minutes 
each. Afterwards, membranes were incubated for 1 hour at room temperature with a 
Horseradish Peroxidase Conjugated Secondary Anti-Rabbit antibody (BioRad, Hercules, 
CA, USA). Then, membranes were washed with TBS-Tween as previously described. The 
membranes were developed using Immun-Star WesternC Chemiluminescent Kit (Bio-Rad, 
Hercules, CA, USA) and exposed to Amersham Hyperfilm (GE Healthcare). To ascertain 
equal loading of protein, the membranes were stripped and reprobed with a monoclonal 
mouse antibody against β-Actin (Sigma- Aldrich®, Germany), diluted 1:8000 in blocking 
buffer. 
Finally, films were digitalized and optical densities of visible bands were 
determined using QuantityOne® Software version 4.6.6 (Biorad, Hercules, CA, USA). 
Results were further presented as fold variation in comparison to our experimental control 
(Mock). 
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4. Chromatin immunoprecipitation (ChIP) and analysis by qRT-PCR 
ChIP was performed using EZ-Magna ChIP™ G – One-Day Chromatin 
Immunoprecipitation Kit (Millipore, MA, USA) according to manufacturer‟s instructions. 
 
 4.1 In vivo crosslinking and lysis 
 LNCaP and DU145 cell lines were treated with DAC and TSA as previously 
mentioned. To each flask formaldehyde was added until a final concentration of 1% was 
reached, followed by a gentle swirl to mix the formaldehyde with culture medium. 
Afterwards, the flaks were left to incubate for 10 minutes at room temperature. 2mL of 10x 
glycine were added in each dish in order to quench unreacted formaldehyde, followed by a 
gentle swirl and an incubation of 5 minutes at room temperature. After the incubation time, 
flasks were placed on ice. 
 The culture medium was carefully removed and 20mL of cold 1x PBS were added 
in order to wash the cells. PBS was removed and a new wash was similarly performed. 
Finally, cells were scrapped and resuspended into microfuge tubes containing 2mL of cold 
1x PBS and 1x Protease Inhibitor Cocktail II (PIC), which were then centrifuged at 800 x g 
for 5 minutes, at 4ºC, to pellet the cells. Supernatant was discarded and cells were 
suspended in 0.5mL of 1x Cell Lysis Buffer and 1x PIC, followed by an incubation on ice 
for 15 minutes, making sure that tubes were vortexed every 5 minutes. Tubes were 
centrifuged again (800 x g for 5 minutes, at 4ºC), supernatant was removed and 0.5mL of 
1x Nuclear Lysis Buffer and 1x PIC were added and the pellet resuspended. 
4.2 Sonication to shear DNA 
For optimal sonication, approximately 300µL of resuspended pellet were 
distributed into fresh microfuge tubes. Sonication was performed for 20 minutes on iced 
water using a Bioruptor® Standard (Diagenode, Philadelphia, PA, USA), with cycles of 20 
seconds with sonication ON, followed by 50 seconds with sonication OFF. Sonicated 
chromatin was stored into fresh microfuge tubes in 50µL aliquots, at -80ºC, until further 
use. 
In order to test the sonication, 5µL of sonicated chromatin was incubated with 10µg  
of RNase (Sigma-Aldrich, Germany) at 37ºC for 30 minutes, followed by an addition of 
1µL of Proteinase K and an incubation at 62ºC for 2 hours. After that, sample was loaded 
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into a 2% agarose gel and run for 1 hour, at 140 V, and was observed in an ultraviolet 
transilluminator [Pharmacia Biotech ImageMaster VDS (Pharmacia Biotech, Bay Area)] in 
order to validate the sonication. 
 
4.3 Immunoprecipitation of crosslinked protein/DNA 
 For a single immunoprecipitation it is required 450µL 1x Dilution Buffer and 
2.25µL 1x PIC. In order to guarantee identical conditions between each 
immunoprecipitation, all sonicated chromatin was primarily treated into the same 15mL 
falcon tube. Hence, the 50µL aliquots of sonicated chromatin were diluted in the respective 
volume of Dilution Buffer with PIC.  5µL of this solution was reserved into a fresh tube to 
use as input control, being stored at 4ºC until elution of protein/DNA complexes and 
reverse crosslink of protein/DNA complexes to free DNA, as described below. 
 Afterwards, 450 µL of the previously made solution were deposited into fresh 
microfuge tubes and the antibodies were added [50µL of anti-H2A (ab18262, Abcam, 
Cambridge, UK), 5µL of anti-H2A.Z (ab4174, Abcam, Cambridge, UK), 10µL of anti-
AcH2A.Z (ab18262, Abcam, Cambridge, UK), 5µL of anti-H3 (ab1791, Abcam, 
Cambridge, UK), 5µL of anti-AcH3 (06-599, Millipore, MA, USA), 5µL of anti-
H3K4me2 (ab32356, Abcam, Cambridge, UK), 5µL of anti-H3K27me3 (07-499, 
Millipore, MA, USA)], 1µL of the positive control anti-RNA Polymerase II and 1µL of the 
negative control Normal Mouse IgG, the last two provided with the kit. Furthermore, 20µL 
of fully suspended protein G magnetic beads were added to the tubes. Microfuge tubes 
were then incubated overnight with rotation, at 4ºC. 
 On the next day, protein G magnetic beads were pelleted using a magnetic separator 
(Magma Grip Rack) (Millipore, MA, USA) and the supernatant was removed. After that, 
beads were fully resuspended and washed for 5 minutes, with constant rotation, with four 
different buffers in the following order: 
o Low Salt immune Complex Wash Buffer; 
o High Salt Immune Complex Wash Buffer; 
o LiCl Immune Complex Wash Buffer; 
o and TE Buffer. 
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4.4 Elution of protein/DNA complexes and reverse crosslink of 
protein/DNA complexes to free DNA 
 In each tube were added 100µL of ChIP Elution Buffer and 1µL of Proteinase K 
and they were incubated for 2 hours at 62ºC, with permanent shaking. Afterwards, tubes 
were incubated during 10 minutes, at 95ºC, and they were allowed to cool until they 
reached room temperature. Beads were separated using the magnetic separator and the 
supernatant was reserved into fresh microfuge tubes. 
4.5 DNA purification using spin columns 
 For each immunoprecipitation, 500µL of Bind Reagent “A” were added to a Spin 
Filter within a Collection Tube. Tubes were centrifuged at 12,600 x g for 30 seconds, and 
the eluate was discarded (both filter and collection tube were saved). 500µL of Wash 
Reagent “B” were added into the same Spin Filter, a new centrifugation was performed 
(12,600 x g for 30 seconds), the eluate was again discarded and another centrifugation took 
place (12,000 x g for 1 minute). Finally, the Spin Filter was put into a fresh collection tube, 
50 µL of Elution Buffer “C” were added directly onto the center of the white Spin Filter 
Membrane and a centrifugation was performed (12,600 x g for 30 seconds). The Spin Filter 
was discarded and the Collection Tube containing the purified DNA was stored at -20ºC 
until further use. 
4.6 Real-time quantitative PCR (qRT-PCR) 
 A real-time quantitative PCR was performed in order to analyze the specific prost-
translational histone marks nearby H2AFZ and SIRT1 gene promoters. Therefore three 
pairs of primers were designed for each gene, being the primers “A” those closer to the 
TSS and primers “C” those which were farthest from the TSS. Information about the 
primers used is compelled in Table 5. 
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Table 7 – qRT-PCR primers features: sequence, distance from TSS and annealing temperature. 
 
The assays were performed separately in 96-well plates in 7500 Real Time PCR 
System (Applied Biosystems, Foster City, CA, USA), according to the recommended 
protocol. 
In short, in each well 2µL of sonicated chromatin, 10µL of Power SYBR® Green 
PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 1µL of primers solution 
(forward + reverse) (10mM) and 7µL DEPC-treated water (MP Biomedicals, OH, USA) 
were added. PCR conditions were those previously defined by manufacturer: 50ºC for 2 
minutes, 95ºC for 10 minutes, 45 cycles at 95ºC for 15 seconds and 60/62ºC for 1 minute, 
95ºC for 15 seconds, 60/62ºC for 20 seconds and, finally, 95ºC for 15 seconds.  
All samples were run in triplicate. gDNA extracted from LNCaP cell line was used 
to prepare five consecutive gDNA dilutions (dilution factor of 10x) that were used as 
standards on each plate, allowing the construction of a standard curve for relative 
quantification and PCR efficiency assessment. Furthermore, multiple water blanks were 
added to each plate as negative controls. 
The results were analyzed using the 7500 Software for 7500 and 7500 Fast Real 
Time PCR Systems V2.0.6 (Applied Biosystems, Foster City, CA, USA). A run was 
considered valid when the slope of the corresponding standard curve was above -3.60 
(corresponding to a PCR efficiency >90%) and the R
2
 of at least three relevant points 
exceeded 0.98. 
Gene Primer Sequence 
Distance 
from TSS 
TANNEALING 
(ºC) 
H2AFZ 
A 
Forward 5' agcgtagctcgctctgtttc 3' 
228bp 60 
Reverse 5' atgagcaagcgaagaaaagg 3' 
B 
Forward 5' gtgacttggcttcaccgtt 3' 
733bp 60 
Reverse 5' ttcttccgtctaggcgagtc 3' 
C 
Forward 5' agacactactgtccccaagca 3' 
1140bp 60 
Reverse 5' gtccatgcaatgcaatcagt 3' 
SIRT1 
A 
Forward 5' tacacttcaggaagacgtggaa 3' 
310bp 62 
Reverse 5' ccgctttctcaacttctctttc 3' 
B 
Forward 5' tgcacgtgagaaaactgagg 3' 
714bp 62 
Reverse 5' acctttgacgtggaggtttg 3' 
C 
Forward 5' tatggccagaacccatactagg 3' 
1127bp 60 
Reverse 5' ggacccatataacccatggtag 3' 
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After the experiment, ChIP-qPCR needs to be normalized. Normalization was 
conducted using the Input Percent Method, where signals obtained from the ChIP were 
divided by signals obtained from the input sample, the last one representing the amount of 
chromatin used for immunoprecipitation.  
 
5. Proximity ligation assay (PLA) 
One PCa cell line, PC-3, cultured in 1cm
2
 coverslips, was exposed to TSA, alone or 
combined with DAC, and to RES, as previously  mentioned. Additionally, Mock cells were 
used as controls, since they were submitted to the medium change procedure, but were not 
exposed to any of the selected drugs. 
Ended the treatment procedure, cells were fixed in 4% formaldehyde (Sigma-
Aldrich, Germany) for 10 minutes, and subsequently stored in methanol, at -20ºC, until 
further use. Immediately before PLA procedure, cells were permeabilized in 0.5% Triton 
X-100 (Sigma-Aldrich, Germany), for 5 minutes, at room temperature and with gentle mix. 
PLA assay was performed using the commercial kit Duolink® In Situ (OLINK 
Bioscience, Uppsala, Sweden), according to manufacturer‟s instructions. The antibodies 
used were anti-sirtuin 1 (ab110304, Abcam, Cambridge, UK) and anti-H2A.Z (#2718, Cell 
Signaling Technology®, MA, USA), diluted 1:200 and 1:50, respectively. After the 
procedure, slides were analysed using fluorescent microscopy (Olympus IX51, Olympus, 
UK). 
 
6. Expression analysis in clinical samples 
6.1 Sample collection 
 Fifty prostate tumor samples were prospectively collected from patients diagnosed 
for prostate carcinoma. Those patients were diagnosed and treated with radical 
prostatectomy at the Portuguese Oncology Institute – Porto, Portugal. The ten 
morphological normal prostate tissues, used as controls, were obtained from patients 
submitted to radical cystoprostatectomy for bladder cancer. 
 After surgery, all tissues specimens were promptly frozen at -80ºC and 
subsequently cut in a cryostat for nucleic acid extraction.  The bulk material was routinely 
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fixed in buffered formalin and paraffin-embedded. The corresponding hematoxylin-eosin 
stained sections were examined by a pathologist to determine tumor type, grade 
classification, Gleason score and pathological stage according to the TNM staging system. 
 Relevant clinical data was collected from patient‟s clinical records. Patients for this 
study were enrolled after informed consent. These studies were approved by the 
institutional review board (Comissão de Ética) of Portuguese Oncology Institute – Porto, 
Portugal. 
 
6.2 RNA Extraction 
 Total RNA extraction was performed in 50 prostate carcinoma samples and 10 
normal prostatic tissue using PureLink™ RNA Mini Kit (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer‟s instructions. Briefly, 750µL of TRIzol® Reagent 
(Invitrogen, Carlsbad, CA, USA) were added to each 1.5mL tube containing tissue 
samples. Then, tissue was homogenized using a rotor-stator and 750µL of TRIzol® 
Reagent were added again. Tubes were incubated at room temperature for 8 minutes and, 
subsequently, 300µL of chloroform (Merck, Germany) were added. Tubes were hand 
shaken for 15 seconds and the mixture was incubated for 3 minutes at room temperature, 
followed by a 15 minutes centrifugation at 12,000 x g and 4ºC. Afterwards, 600µL of the 
upper, aqueous phase containing the RNA were transferred to a new RNAse-free tube, 
600µL of 70% (v/v) of ethanol were added and tubes were vigorously shaken. 
Subsequently, 700µL of the previous solution were transferred to a Spin Cartridge, which 
was placed in a Collection Tube, and a centrifugation took place (12,000 x g for 15 
seconds, at room temperature). The eluate was discarded and the remaining volume of the 
solution containing the aqueous phase and 70% (v/v) ethanol was transferred to the same 
Spin Cartridge and a new centrifugation was performed. When all the solution had been 
processed, 700µL of Wash Buffer I were added to the Spin Cartridge and it was 
centrifuged at 12,000 x g for 15 seconds, at room temperature. Then, the Spin Cartridge 
was placed onto a new Collection Tube and 500µL of Wash Buffer II were added. After 
centrifugation (12,000 x g for 15 seconds), another wash with Wash Buffer II was done, 
followed by a 1-minute centrifugation. Finally, the Spin Cartridge was placed in a new 
tube in order to recover the RNA by elution, and 50µL of RNAse-free water was added to 
the center of the membrane, followed by incubation for 3 minutes at room temperature and 
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a centrifugation for 2 minutes (12,000 x g, at room temperature). A new elution step was 
performed for a final volume of 100µL. RNA concentration and purity ratios were 
evaluated using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
USA). RNA quality was assessed by a run in an agarose gel and RNA samples were stored 
at -80ºC until further use.  
 
6.3 DNAse treatment 
 In order to remove any genomic DNA present in our samples after RNA extraction, 
treatment with DNase was performed, using TURBO DNA-free™ (Ambion, Applied 
Biosystems, Foster City, CA, USA) according to the protocol suggested by manufacturer, 
as previously described. 
 
6.4 cDNA synthesis 
 For gene expression analysis, cDNA was synthesized by reverse transcription using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, 
USA), according to manufacturer‟s protocol, as previously described. 
 
6.5 Quantitative reverse transcriptase PCR (qRT-PCR) 
H2AFZ and SIRT1 transcripts were quantified by real time quantitative PCR. The 
assays were performed using pre-made gene expression assays for H2AFZ 
(Hs01888362_g1, Applied Biosystems, Foster City, CA, USA) and SIRT1 
(Hs01009005_m1, Applied Biosystems, Foster City, CA, USA) and the endogenous 
control GUSB (Hs99999908_m1, Applied Biosystems, Foster City, CA, USA), the latter 
used to normalize cDNA input. The expression assays were performed separately in 96-
well plates in 7500 Real Time PCR System (Applied Biosystems, Foster City, CA, USA), 
according to the recommended protocol, as previously described. 
 
7. Statistical Analysis 
In cell lines, differences in transcript levels of H2AFZ and SIRT1 between the 
treatments performed were determined using an One-Way Analysis of Variance (one-Way 
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ANOVA) test, followed by a multiple comparison Dunnett‟s test, comparing all groups 
against the Mock. Differences regarding H2A.Z and sirtuin 1 protein levels were also 
evaluated using an One-Way Analysis of Variance (one-Way ANOVA) test, followed by a 
multiple comparison Dunnett‟s test, comparing all groups against the experimental control. 
Differences in quantitative expression levels of SIRT1 and H2AFZ between PCa 
samples and normal prostate tissues were assessed by the nonparametric Mann-Whitney U-
test. The relationship between expression levels and other standard clinicopathological 
variables such as Gleason score and pathological stage were assessed using the Kruskal-
Wallis or the Mann-Whitney tests, as appropriate. 
All tests were two-sided and p-values were considered significant when inferior to 
0.05. Statistical analysis was performed using GraphPad Prism version 5.0 for Windows 
(GraphPad Software, CA, USA). Graphs were built using GraphPad Prism version 5.0 for 
Windows (GraphPad Software, CA, USA). 
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1. Epigenetic modulating drugs lead to an increase in H2AFZ transcript 
levels with a concomitant decrease of its protein levels 
 In order to investigate whether DAC and/or TSA might induce alterations in 
H2AFZ transcript levels, three PCa cell lines (LNCaP, PC-3 and DU145) were exposed to 
these drugs, either alone or in combination (Figure 16).  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
DAC alone did not induce any alteration in H2AFZ transcript levels, whereas 
exposure to TSA alone or combined with DAC significantly increased the H2AFZ mRNA 
Figure 16 – Transcript levels of H2AFZ in three distinct cell lines (A- LNCaP, B- PC-3 and                    
C- DU145) after exposure to DAC and/or TSA. The results are presented as fold variation in 
comparison to the experimental control. 
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levels in all tested cell lines (p<0.001). Indeed, the highest H2AFZ transcript levels were 
obtained after combined treatment. 
Furthermore, protein levels of this histone variant were also assessed by Western 
Blot (Figure 17). 
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Figure 17 – Results for (A) Western Blot and (B) fold variation of optical density for H2A.Z 
protein levels in (1) LNCaP, (2) PC-3 and (3) DU145 cell lines. Results were normalized using the 
constitutive protein β-actin and presented as fold variation in comparison with Mock.  
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Unexpectadly, H2AFZ protein levels followed the opposite trend of the transcript 
levels as they significantly decreased after exposure to TSA (p<0.01 for LNCaP and 
DU145 and p<0.001 for PC-3) and TSA combined with DAC (p<0.001). 
 
2. Cell lines exposure to TSA alone or combined with DAC induces 
enrichment in transcription activation marks of histones in the vicinity of 
H2AFZ transcription start site 
 After treatment with TSA alone or combined with DAC, chromatin 
immunoprecipitation was performed in LNCaP and DU145 cell lines. Since DAC alone 
did not affect H2AFZ transcript and protein levels, the effect of this treatment on histone 
marks was not further studied. Chromatin of treated cell lines was immunoprecipitated for 
several transcriptional activating histone marks (acH2A.Z, acH3 and H3K4me2) and for a 
repression histone mark (H3K27me3). Immunoprecipitation for H2A, H2A.Z and H3 was 
also performed. After ChIP, qRT-PCR was carried out to evaluate accumulation of marks 
along the H2AFZ promoter region (Figures 18 and 19). 
 Interestingly, for both LNCaP and DU145 cell lines, no relevant differences in H2A 
and H2A.Z levels were observed after treatment. However, H2A tended to accumulate in 
zones distant from the TSS while H2A.Z was enriched near the TSS. Remarkably, 
acH2A.Z increased mostly nearer to the TSS in PCa cells exposed to TSA. Contrarily, H3 
levels did not change significantly along H2AFZ promoter in both cell lines after treatment. 
Concerning H3 activation marks, AcH3 and H3K4me2, an increase nearer to the TSS was 
observed after drug(s) exposure. Nevertheless, no variations were observed for the 
H3K27me3 repressive mark along the entire H2AFZ promoter. 
 
 
 
 
. 
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Figure 18 – ChIP assay results for LNCaP cell line regarding (A) H2A, (B) H2A.Z,                     
(C) AcH2A.Z, (D) H3, (E) AcH3, (F) H3K4me2 and (G) H3K27me3 histones and histones marks 
across H2AFZ promoter. Results are normalized with the input of total sonicated chromatin 
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Figure 19 - ChIP results for DU145 cell line concerning (A) H2A, (B) H2A.Z, (C) AcH2A.Z,           
(D) H3, (E) AcH3, (F) H3K4me2 and (G) H4K27me3 histones and histones marks across H2AFZ 
promoter. Results are normalized with the input of total sonicated chromatin. 
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3. Epigenetic modulating drugs increase SIRT1 transcript and protein 
levels 
Because it has been recently suggested that sirtuin 1 might degrade H2A.Z, 
transcript levels of SIRT1 were also assessed in the same three cell lines which were 
exposed to epigenetic-modulating drugs (Figure 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
jj 
 
  
Remarkably, whereas DAC alone did not alter SIRT1 mRNA levels, a statistically 
significant increase was observed for all PCa cell lines exposed to TSA (p<0.001 for 
LNCaP and p<0.01 for PC-3 and DU124) and TSA combined with DAC (p<0.001 for all 
three cell lines).  
Figure 20 – Transcript levels of SIRT1 in three distinct cell lines – (A) LNCaP, (B) PC-3 and      
(C) DU145 – after exposure to DAC and/or TSA. The results are presented as fold variation in 
comparison to our control. 
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Sirtuin 1 
β-actin 
Sirtuin 1 
β-actin 
Sirtuin 1 
β-actin 
Simultaneously, protein levels of sirtuin 1 were also assessed (Figure 21) and these 
significantly increased after TSA exposure in LNCaP and DU145 cell lines (p<0.001) and, 
more impressively, after exposure to DAC and TSA (p<0.001). 
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Figure 21 – Results for (A) Western Blot and (B) fold variation of optical density for H2A.Z 
protein levels in (1) LNCaP, (2) PC-3 and (3) DU145 cell lines. Results were normalized using the 
constitutive protein β-actin and presented as fold variation in comparison with the control. 
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4. Exposure of PCa cell lines to TSA alone or combined with DAC results in 
an enrichment of transcriptional activation marks in histones neighboring 
the SIRT1 transcription start site  
 Similar to the observations on the H2AFZ gene promoter, drug exposure did not 
alter the deposition of H2A and H2A.Z across the SIRT1 gene promoter. However, H2A.Z 
was preferentially located at nucleosomes near the TSS, whereas H2A was preferentially 
located within the nucleosomes more distant from the TSS. Nonetheless, levels of 
AcH2A.Z were not altered by epigenetic treatment, and these were dispersed along the 
SIRT1 promoter (Figures 22 and 23). 
 While in DU145 cell line the levels of H3 were stable along the promoter and after 
treatment, in LNCaP cells that trend was not so obvious, although relevant differences 
were not apparent. In addition, in both PCa cell lines there was an increase in marks 
responsible for gene transcription activation (AcH3 and H3K4me2) after drug(s) exposure, 
being more enriched in nucleosomes nearer to the TSS. Remarkably, the repressive mark 
H3K27me3 decreased after TSA exposure, either alone or in combination with DAC.  
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C 
Figure 22 – ChIP for LNCaP cell line regarding (A) H2A, (B) H2A.Z, (C) AcH2A.Z, (D) H3,             
(E) AcH3, (F) H3K4me2 and (G) H4K27me3 histones and histone marks along SIRT1 promoter. 
Results were normalized with the input of total sonicated chromatin. 
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Figure 23 – ChIP  results for DU145 cell line regarding (A) H2A, (B) H2A.Z, (C) AcH2A.Z,         
(D) H3, (E) AcH3, (F) H3K4me2 and (G) H4K27me3 histones and histones marks across SIRT1 
promoter. Results are normalized with the input of total sonicated chromatin. 
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5. Nicotinamide (NIC) exposure is associated with H2A.Z overexpression  
 To evaluate the effect of sirtuin 1 inhibition on H2A.Z protein levels, cell lines 
(LNCaP, PC-3 and DU145) were treated with the former epigenetic modulating drugs 
(TSA and DAC) and with NIC, a sirtuin 1 inhibitor. Western blot analysis was performed 
to determine protein levels profile following treatment (Figure 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subsequently, optical density was determined to allow for protein quantity 
comparison among the different treatment modalities (Figure 25). 
 
 
 
Figure 24 – Western Blot for sirtuin 1, H2A.Z and the constitutive protein β-actin for three 
prostate cancer cell lines (LNCaP, PC-3 and DU145) after exposure to NIC, alone or combined 
with epigenetic drugs. 
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Overall, the three cell lines exposed to NIC showed a decrease in sirtuin 1 levels 
with a concomitant increase in H2A.Z protein levels (Figure 24 and Figure 25). In LNCaP 
cells, sirtuin 1 levels decreased after the exposure to NIC, alone or combined with both 
Figure 25 – Optical densities of (A) sirtuin 1 and (B) H2A.Z for (1) LNCaP, (2) PC-3 and            
(3) DU145 cell lines after exposition to NIC and/or epigenetic modulating drugs. Results were 
normalized with β-actin levels and presented as fold variation in comparison with the control 
experiment. 
 
Dunnett‟s test, * p<0.05; ** p<0.01; *** p<0.001 
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epigenetic drugs (p<0.001). For DU145 the same was observed but only for cells exposed 
to NIC alone or combined with TSA (p<0.001). Contrarily, in PC-3, sirtuin 1 levels 
increased after treatment with NIC combined with TSA or DAC plus TSA (p<0.05 and 
p<0.001, respectively). Remarkably, PC3 cells exposed to NIC alone showed a statistically 
significant decrease in sirtuin 1 levels (p<0.01). 
 H2A.Z protein levels increased after inhibition of sirtuin 1 in two of the cell lines 
(DU145 and PC-3) (p<0.001) and a more dramatic effect was disclosed when NIC was 
combined with TSA (p<0.05) or with DAC plus TSA (p<0.001). 
 Hence, the use of NIC alone or combined with TSA, TSA alone or TSA plus DAC, 
caused a general decrease of sirtuin 1 levels and a simultaneous increase in H2A.Z protein 
levels.  
 
6. Treatment with resveratrol (RES) is associated with H2A.Z 
underexpression  
 Since inhibition of sirtuin 1 was associated with H2A.Z overexpression, we 
evaluated the opposite effect. Thus, cells were exposed to RES, a selective activator of 
sirtuin 1, and to epigenetic drugs. Protein levels of both sirtuin 1 and H2A.Z were assessed 
by Western Blot. As expected, exposure to RES induced a decrease in H2A.Z levels and an 
increase of sirtuin 1 levels in all PCa cell lines (Figure 26).  
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Exposure to RES induced lower levels of H2A.Z and higher levels of sirtuin 1 in all 
PCa cell lines (Figure 26). Subsequently, optical density was determined to allow for 
protein quantity comparison among the different treatment modalities (Figure 25). 
 
 
 
 
 
Figure 26 – Western Blot for sirtuin 1, H2A.Z and the constitutive protein β-actin for three prostate 
cancer cell lines (LNCaP, PC-3 and Du145) after exposition to RES, alone or combined with 
epigenetic modulating drugs. 
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 Using optical density analysis, sirtuin 1 protein levels were shown to be 
significantly increased after PCa cell lines exposure to RES (p<0.001 for LNCaP and 
p<0.01 for PC-3 and DU145) (Figure 27). This trend was more impressive when 
Figure 27 – Optical densities of (A) sirtuin 1 and (2) H2A.Z for (1) LNCaP, (2) PC-3 and            
(3) DU145 cell lines after exposition to RES and epigenetic modulating drugs. Results were 
normalized with β-actin levels and presented as fold variation in comparison with the control 
experiment. 
 
Dunnett‟s test, * p<0.05; ** p<0.01; *** p<0.001 
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resveratrol was combined with epigenetic modulating drugs (p<0.001), and when the 
sirtuin 1 activator was used simultaneously with DAC and TSA. 
 The opposite effect was observed for H2A.Z levels: cell lines exposed to RES 
showed decreased H2A.Z levels (p<0.05 for PC-3 and p<0.001 for LNCaP and DU145). 
Interestingly, the lowest levels of H2A.Z were found in PCa cell lines treated with RES in 
combination with DAC and TSA (p<0.001). 
Thus, the use of RES alone or combined with TSA or TSA plus DAC, was 
associated with an overall increase of sirtuin 1 levels, and a concomitant decrease in 
H2A.Z protein levels. 
  
7. Epigenetic modulating drugs promote the interaction between sirtuin 1 
and H2A.Z 
In order to validate wether epignetic modulating drugs regulates the interaction 
between sirtuin 1 and H2A.Z, a crutial step to promote the degradation of the latter, a PLA 
assay was performed in PC-3 PCa cancer cells (Figure 28). 
 Interestingly, and after exposure to epigenetic modulating drugs, the interaction 
between sirtuin 1 and H2A.Z abruptly increased, in comparison to the untreated control, 
Mock. Additionally, the results obtained when the combined treatment with DAC and TSA 
was used were quite similar to those observed after exposure to RES. 
 
 
 
 
 
 
V - RESULTS 
75 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mock 0.5µM TSA 
D
A
P
I 
T
R
IT
C
 
M
er
g
ed
 
F
ig
u
re
 2
8
  
- 
L
eg
en
d
 o
n
 t
h
e 
n
ex
t 
p
ag
e.
 
V - RESULTS 
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1µM DAC + 0.5µM TSA 40µM RES 
D
A
P
I 
T
R
IT
C
 
M
er
g
ed
 
F
ig
u
re
 2
8
  
- 
D
et
ec
ti
o
n
 o
f 
si
rt
u
in
 1
 a
n
d
 H
2
A
.Z
 i
n
te
ra
ct
io
n
 i
n
 P
C
-3
 c
el
l 
li
n
es
, 
b
ef
o
re
 a
n
d
 a
ft
er
 t
re
at
m
en
t 
w
it
h
 e
p
ig
en
et
ic
 m
o
d
u
la
ti
n
g
 d
ru
g
s.
 P
L
A
 
si
g
n
al
s 
ar
e 
sh
o
w
n
 i
n
 r
ed
 a
n
d
 t
h
e 
n
u
cl
ei
 i
n
 b
lu
e.
 M
ag
n
if
ic
at
io
n
: 
4
0
x
. 
 
V - RESULTS 
77 
 
8. H2AFZ is overexpressed and SIRT1 is underexpressed in primary 
prostate cancer tissues  
H2AFZ and SIRT1 transcript levels were assessed in primary tumors and in normal 
prostatic tissue NPT. Relevant clinical and histopathological data was collected form 
clinical charts (Table 8). No statistically significant differences were found between the 
age of PCa patients and controls. 
 
Table 8 - Clinical and histopathological features of patients with PCa and normal prostate (NPT). 
Clinicopathological Features PCa NPT 
Patients, n 50 10 
Median age, median (range) 66 (51 - 74) 63 (45 - 79) 
PSA (ng/mL), median (range) 9.05 (2.66 - 35.50) n.a.
*
 
Pathological Stage, n (%)   
pT2 18 (36) n.a.
*
 
pT3 32 (64) n.a.
*
 
Gleason Score, n (%)   
< 7 9 (18) n.a.
*
 
= 7 36 (72) n.a.
*
 
> 7 5 (10) n.a.
*
 
*
not available or not applicable 
 
Statistically significant differences in SIRT1 and H2AFZ transcript levels between 
PCa and NPT samples were found (p<0.0001). In fact, tumors displayed a significant 
underexpression of SIRT1 and a concomitant overexpression of H2AFZ (Figure 29). 
Statistical analysis did not disclosure any association between SIRT1 and H2AFZ 
expression levels and the clinicopathological variables of PCa patients. 
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Figure 29 – Distribution of (A) SIRT1 and (B) H2AFZ relative expression in primary prostate 
tumor (PCa) and normal prostate tissue (NPT).  
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VI – DISCUSSION 
 
It is widely acknowledged that cancer is caused by the accumulation of genetic and 
epigenetic changes. These alterations result in neoplastic transformation, a process in 
which neoplastic cells acquire a gene expression profile completely unique and distinct 
from normal cells [4, 149]. The identification of these profiles has been intensively studied 
and resulted in a better understanding of tumor biology over the last years. Furthermore, 
this knowledge might be useful for both cancer diagnosis and prognosis assessment, and 
might ultimately contribute for a more effective therapeutic approach [106, 150]. 
Although several studies have reported the effects of epigenetic drugs in some well-
known cancer-related genes, mostly tumor suppressor genes [130, 135], there is scarce 
information concerning the impact of those drugs in expression regulation of genes 
codifying histone variants, which might influence nucleosome assembly. One of the 
histone variants that has been studied is H2A.Z. The role of this histone variant in gene 
transcription regulation is controversial at present, since it has been related both with 
inactive and active transcription sites of chromatin [151, 152]. Nonetheless, deregulation of 
this variant have been implicated in several tumor models [50, 153], but not in prostate 
cancer. Thus, we undertook the task of evaluating the effect of epigenetic modulating 
drugs on the regulation of H2A.Z expression in PCa. 
Firstly, three PCa cell lines were submitted to treatment with DAC and/or TSA, and 
transcript and protein levels of H2AFZ were assessed. We demonstrated that in PCa cell 
lines, exposure to epigenetic drugs – TSA alone and in combination with DAC – results in 
increased levels of H2AFZ transcript. In fact, the combined treatment with both TSA and 
DAC induced the highest levels of H2AFZ mRNA, advocating a synergistic effect of both 
drugs, in line with previous reports [154]. Importantly, the increased transcript levels were 
corroborated by ChIP assay results, which demonstrated an increase in histone activating 
marks, such as AcH3 and H3K4me2 nearby the TSS. Interestingly, in PCa cell lines treated 
with epigenetic drugs, AcH2A.Z increased nearby the TSS, contrarily to the total H2A.Z, 
which remained unchanged. This finding is in accordance in previous reports that have 
associated this epigenetic mark with gene transcription activation [126], thus justifying the 
increased levels of H2AFZ transcript after PCa cells exposure to TSA. Nevertheless, a 
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decrease in H2A.Z protein levels was, unexpectedly, observed, suggesting a post-
translational mechanism regulating the protein levels of this histone variant. 
Accordingly and because sirtuin 1 has been reported to negatively regulate H2A.Z, 
inducing its degradation in cardiomyocytes [66], we investigated whether epigenetic drugs 
might also affect SIRT1 transcription. Indeed, we found that SIRT1 expression was 
increased in PCa cell lines exposed to TSA, both at transcript and protein level. Moreover, 
an enrichment in activating marks (specifically AcH3 and H3K4me2) was observed near 
the TSS of SIRT1, with a concomitant decrease of the repressive mark H3K27me3 [155]. 
Thus, our results suggest that epigenetic modulating drugs are able to increase the 
expression of this gene through modifications of the histone marks. Interestingly, levels of 
AcH2A.Z were rather low and were not altered by the epigenetic treatment. This finding is 
in accordance with previous studies which have found that, in PCa cell lines, genes not 
actively transcribed exhibit lower levels of acH2A.Z [126]. 
To further clarify the putative role of H2A.Z regulation by sirtuin 1 in PCa cell 
lines, we tested the effect of an inhibitor (NIC) and an activator (RES) of sirtuin 1 on 
H2A.Z and sirtuin 1 levels [57, 58]. Surprisingly, NIC induced a decrease of sirtuin 1 
protein levels. Although unexpected, this has been already reported for leukemic cells 
[156, 157]. However, our results demonstrate that even in the presence of NIC, exposure to 
epigenetic drugs is able to increase sirtuin 1 levels. Remarkably, in the latter conditions, 
H2A.Z protein levels are increased in our in vitro model, contrarily to the exposure to 
epigenetic drugs in the absence of NIC. Thus, although sirtuin 1 levels are increased, NIC 
is effectively inhibiting sirtuin 1 negative regulation upon H2A.Z through 
ubiquitin/proteasome-dependent pathway. Conversely, RES alone or combined with 
epigenetic modulating drugs was associated with decreased H2A.Z protein levels. 
Interestingly, exposure to RES alone induced an increase in sirtuin 1 protein levels. 
Although the mechanism can not be derived directly from our data, it has been shown that 
RES induces SIRT1 expression [158]. Thus, the combined effect of activation and induced 
expression of sirtuin 1 by RES justifies the observed decrease in H2A.Z protein levels. 
Furthermore, exposure to epigenetic drugs just magnifies this effect, mainly through the 
increased of SIRT1 gene expression, as expected from the first experiments. 
Concerning the mechanism that regulates H2A.Z incorporation into nucleosomes, 
there is still limited information [159]. However, it is known that the ATP dependent 
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nucleosome remodeler SNF-2-related CREB-binding protein activator protein (SRCAP) 
not only inserts H2A.Z into nucleosomes, but is also able to deposit it near gene promoters 
[159-161]. Remarkably, SRCAP has already been described to be overexpressed in PCa 
[124, 162]. Hence, the enhanced insertion of H2A.Z observed in PCa cell lines might be 
due to enhanced activity of SRCAP. Nevertheless, H2A.Z can be also incorporated in 
nucleosomes by other complexes, such as p400 [159]. Although a therapy based on 
SRCAP repression would seem attractive, it has been reported that total inhibition of 
H2A.Z insertion into nucleosomes might be pathogenic as well [163, 164]. Hence, a 
therapeutic approach based on H2A.Z degradation, which would not lead to complete loss 
of H2A.Z, has been considered more viable and safe [51]. Indeed, our results demonstrate 
that modulation of H2A.Z levels might be achieved indirectly using epigenetic drugs that 
are able to induce SIRT1 upregulation. Moreover, higher levels of active sirtuin 1 might 
lead to increased deacetylation of Lys-15, triggering a cascade of events that culminates in 
H2A.Z ubiquitylation on Lys-115 and Lys-121 and, ultimately, in its degradation by the 
proteosomal pathway [66]. Interestingly, the PLA assay performed in PC-3 cell line 
showed that, after exposure to epigenetic modulating drugs, the interaction between sirtuin 
1 and H2A.Z dramatically increased, suggesting that these drugs were responsible for the 
promotion of this physical contact, critical for histone variant degradation, as previously 
reported [66]. It has been also reported that sirtuin 1 not only regulates H2A.Z levels, but 
also that H2A.Z might influence SIRT1 expression, existing a reciprocal regulation 
mechanism between both proteins [66, 165]. Interestingly, our results demonstrate that 
H2A.Z within nucleosomes neighboring SIRT1 TSS did not harbor acetylation either 
before or after treatment with DAC and/or TSA. Thus, we might speculate that H2A.Z 
negatively regulates SIRT1 expression, resulting in lower sirtuin 1 levels in PCa cells. This 
hypothesis is supported by our findings that SIRT1 transcript levels are lower in PCa 
tissues compared to normal. There is, however, conflicting data concerning SIRT1 
expression in PCa [64, 65], although it has been recently shown that SIRT1 is a 
haploinsufficient tumor suppressor gene [64]. Nevertheless, further studies are required to 
validate the putative interaction between sirtuin 1 and H2A.Z through colocalization and 
the physical interaction. 
The role of sirtuin 1 in cancer is yet to be fully understood. In fact, SIRT1 is pointed 
out as both a tumor suppressor and an oncogene [166]. One of the main features that 
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validates SIRT1 as an oncogene is its capacity to inhibit p53 through deacetylation, thus 
increasing the likelihood of neoplastic transformation [60]. However, it is also known that 
p53 regulates SIRT1 transcription through a negative feedback loop. Hence, theoretically, 
p53 inactivation lowers SIRT1 activity, which causes increased TP53 activity [167]. The 
same occurs for FOXO3a [167], FOXL2 [168], and E2F1 [169], that might also act as 
tumor suppressors under certain circumstances. Nevertheless, sirtuin 1 has been also 
suggested as a tumor suppressor protein, due to its ability to deacetylate the oncogenic β-
catenin, inactivating it [170]. Indeed, β-catenin is responsible for the growth of human 
colon cancer cell lines [170] and, in addition, it has been already reported that BRCA1 
interacts with sirtuin 1, enhancing the activity of the latter, reducing growth and increasing 
apoptosis in cells [171]. Additionally, is has already been reported that sirtuin 1 is 
responsible for autophagy in PCa cells. Hence, knockdown of this gene induced the 
formation of PIN, a precursor of PCa, suggesting that SIRT1 might be, in fact, a tumor 
suppressor gene in PCa [172]. 
Herein, we also report for the first time that H2AFZ is upregulated in PCa tissues. 
This finding not only indicates that H2A.Z might play a critical role in prostate 
carcinogenesis, but also that this protein might be a putative target for advanced PCa 
therapy, as it has been already proposed for breast cancer [51]. In this vein, the use of 
epigenetic drugs, that are able to indirectly downregulate H2A.Z through SIRT1 
upregulation, might be an attractive strategy to therapeutically target H2A.Z. Nonetheless, 
further studies are required to validate SIRT1 and H2AFZI as targets for epigenetic therapy 
in PCa. 
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VII – CONCLUSIONS 
 
The lack of effective therapeutic strategies for castration-resistant PCa have arose 
the necessity to investigate alternative therapies that might improve treatment of advanced 
PCa. The role of H2A.Z in carcinogenesis has been already reported in PCa, in which the 
acetylated form is responsible for oncogenic activation. Nevertheless, the effects of 
epigenetic drugs on H2A.Z levels have not been previously characterized.  
Herein, we exposed PCa cell lines to epigenetic drugs and found an increase in 
H2AFZ transcript levels, associated with augmented levels of histone activating marks near 
the TSS of H2AFZ, as well as a decrease in H2A.Z protein levels after treatment. Owing to 
the regulatory role of sirtuin 1 on H2A.Z, we further assessed the impact of epigenetic 
drugs on SIRT1 at transcript and protein levels. We found that both were elevated and this 
was associated with enrichment in activating histone marks nearby the TSS of that gene. 
Furthermore, selective inhibition of sirtuin 1 by nicotinamide resulted in increased H2A.Z 
protein levels, whereas the reverse effect was observed following treatment with RES, a 
sirtuin 1 activator. Additionally, exposure of PCa cell lines to epigenetic modulating drugs 
promoted the interaction between both proteins. We, thus, concluded that H2A.Z levels 
may be indirectly regulated by epigenetic drugs, through upregulation of SIRT1. 
Finally, we translated these findings into primary PCa, demonstrating that SIRT1 
was underexpressed compared to normal prostate tissues. Moreover, and for the first time, 
H2AFZ overexpression was verified in PCa. Globally, these results suggest that both genes 
might be attractive targets for epigenetic therapy in PCa patients. 
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VIII – FUTURE PERSPECTIVES 
 
 To validate our postulate that sirtuin 1 induces H2A.Z degradation in PCa cells, two 
complementary studies must be performed: 
 Demonstrate colocalization of sirtuin 1 and H2A.Z, by immunofluorescence; 
 Assess the interaction between sirtuin 1 and H2A.Z, using a proximity ligation 
assay, in LNCaP and Du145 PCa cell lines. 
 
To validate both genes as putative target for PCa epigenetic therapy we must assess, 
in PCa cell lines, the phenotypic impact of: 
 Induction of SIRT1 expression; 
 Silencing of H2AFZ. 
Interestingly, sirtuin1 overexpression will allow the assessment of this effect regarding 
H2A.Z protein levels. 
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